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Limited drug penetration into solid tumors may prevent cancer agents from achieving 
sufficient concentrations to exert their therapeutic effects.  However, most pre-clinical in vitro 
drug discovery studies utilize two dimensional (2D) growth inhibition assays, which do not closely 
recapitulate either the three dimensional (3D) morphology or cellular microenvironments of solid 
tumors. In this study, we investigated the penetration of cancer drugs into 2D and 3D head and 
neck squamous cell carcinoma (HNSCC) cell culture models to determine whether differences in 
drug penetration might contribute to differences in growth inhibition in the two models. Ellipticine, 
idarubicin, daunorubicin and doxorubicin were selected as the test drugs because they are 
fluorescent and a linear relationship exists between fluorescent intensity and drug concentration. 
Cal33 and FaDu HNSCC cell lines were seeded into normal tissue culture microplates to generate 
2D monolayers or Ultra Low Attachment microplates to generate spheroids. We used the Cell Titer 
Glo® reagent to measure cellular ATP levels as an indicator of cell viability and proliferation. The 
ImageXpress Micro automated high content platform was used to acquire fluorescent images of 
2D and 3D cell cultures exposed to the four fluorescent drugs and the Hoechst DNA stain. We 
used the multi-wavelength cell scoring image analysis module to quantify the accumulation and 
distribution of fluorescent drugs in 2D and 3D cell cultures. Although 2D Cal33 cultures were 
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more sensitive than 3D cultures to growth inhibition by all four drugs, both models exhibited 
similar concentration and time dependent drug accumulation characteristics. In 2D, the distribution 
of compounds within cells was uniform and independent of the cell numbers seeded into the wells. 
In Cal33 spheroids however, the compounds exhibited an apparent distribution gradient from high 
in cells in the outer layers to low in cells in the interior. We speculate that the enhanced cell-cell 
and cell-ECM contacts in spheroids forms a barrier through which therapeutic agents must 
penetrate, and that the lower drug concentrations experienced by tumor cells in the interior of 
spheroids combines with their diminished proliferative capacity to confer the apparent resistance 
of 3D cultures to cancer drug induced growth inhibition and cell death.  
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1.0  INTRODUCTION 
1.1 DRUG DEVELOPMENT AND DRUG RESISTANCE 
In the late 1980s, the National Cancer Institute (NCI) developed a panel of 60 well-
characterized cancer cell lines from diverse tumor types, which have been used as a standard 
platform for screening drugs against heterogeneous cancer subtypes. It includes cell lines from the 
9 most frequent cancer lineage types: leukemia, colon, lung, CNS, renal, melanoma, ovarian, 
breast and prostate.[1] This screening model was developed to supplant  murine neoplasms with 
cell lines from human solid tumors and to became an efficient tool for identifying compounds with 
anticancer growth–inhibitory or toxic effects.  The pattern of growth inhibition in the NCI 60 cell 
line panel was similar for compounds of similar mechanism and the development of the 
COMPARE algorithm provided a method to infer the mechanisms of action of novel compounds 
based on the similarity of their growth inhibition profiles to known drugs.[2] Previous studies in 
the NCI60 cell line panel have accumulated large amounts of compound screening data and multi-
level omics data, which include genome-wide genetic alterations, gene expression and protein 
regulation information.[3] These NCI60 datasets were widely utilized for establishing linear 
correlation patterns in order to identify relationship among chemical responses, genetic alterations, 
mRNA expression and protein regulations in the NCI60 cell line panel[4]. There are two main 
methods used for the identification of anti-cancer agents. In the classic approach, compounds from 
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different sources are tested against a panel of cancer cell lines to identify agents that inhibit cell 
growth[5]. If a compound shows growth inhibitory activity in vitro, it’s in vivo tumor efficacy will 
be evaluated in mice. Novel targeted approaches develop specific drugs against oncogenic proteins 
and signaling pathways. Computer-assisted drug design and high throughput screens are 
commonly utilized to identify compounds with anti-cancer activity. An evaluation of antitumor 
activities and determination of the mechanism(s) of action are necessary for further 
development.[5] However, most preclinical in vitro  drug discovery studies employ  growth 
inhibition assays  and genetic alteration studies conducted  in two-dimensional (2D) cell culture 
models[6]. In addition, the NCI 60 panel does not include cell lines derived from some common 
forms of human cancer, including head and neck squamous cell carcinoma (HNSCC). 
Drug resistance in tumors is a major problem in current cancer drug development. Resistance 
to chemotherapy can be divided into two categories: intrinsic and acquired.[7] Intrinsic drug 
resistance is caused by molecular and genetic heterogeneity, cancer stem cells components of 
tumors, and the tumor microenvironment. Thus, the intrinsic drug resistance pre-exits in tumor 
cells and prevents chemotherapeutics from being effective. Moreover, tumor resistance can be 
acquired by tumors exposed to anticancer drugs: (i) mutations to target proteins  during  treatment 
that alter drug binding, (ii) increased expression of the therapeutic target, and (iii) activation of 
alternative compensatory signaling pathways.[7, 8] Multiple resistance mechanisms may 
cooperate  to account for the failure of cancer drugs in response to therapy. One major multidrug 
resistance (MDR) mechanism in cancer cells is the elevated expression of efflux transporters, 
which causes both intrinsic and acquired drug resistance. The ATP-binding cassette (ABC) 
transporter family regulates the passage of drugs, nutrients and other important molecules across 
the plasma and intracellular membranes. Multi-drug resistance protein 1 (also known as P-gp, 
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ABCB1), MDR-associated protein 1 (also known as MRP1, ABCC1) and breast cancer resistance 
protein (BCRP) are found widely expressed in many human cancers, including pancreatic cancer, 
ovarian cancer and lymphoma cancer. These proteins promote the elimination of various 
hydrophobic anti-cancer compounds, including topoisomerase inhibitors and taxanes [8-10]. 
Other mechanisms of drug resistance include adaptive responses to tumor treatment. Pro-
survival adaptive responses triggered by exposure to antitumor agents can alter tumor cell 
morphology and induce autophagy to reduce the effectiveness of tumor apoptosis [11].  The pro-
survival adaptive responses are also well known as one of the hallmarks of cancer [12]. Mutations, 
amplifications and chromosomal translocations of anti-apoptotic BCL-2 family members [13], 
inhibitor of apoptosis proteins(IAPs) [14], and the caspase 8 inhibitors FLIP [15], are tightly 
associated with the adaptive resistance of tumors to chemotherapies. BCL-2 family proteins are 
known to be important gatekeepers of the apoptotic response that  mainly reside in mitochondria, 
interact with pro-apoptotic effectors and activators directly, and protect these organelles from 
mitochondrial membrane permeabilization (MMP), which is one of the rate-limiting events of 
apoptosis induction [16]. 
Limited penetration of anticancer drugs in solid tumors also contributes to the low efficiency 
of some anticancer drugs [17]. In solid tumors, cancer cells grow in contact with each other, 
stromal cells and the ECM. The uncontrolled proliferation of tumor cells forces blood vessels 
apart, reduces vascular density and creates a population of cells distant (>100μm) from blood 
vessels [18]. Since systemic antitumor drugs gain access to cancer cells via by the blood 
circulation, the increased distance between tumor cells and blood vessels can hamper the 
penetration of chemotherapeutic agents into the cancer cells [19]. Furthermore, the poor vascular 
organization of solid tumors also causes increased extracellular pH and decreased oxygen levels 
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inside tumors [20, 21]. A number of studies indicate that therapeutic agents are less effective in 
the hypoxic and acidic microenvironments of cells in solid tumors [22, 23]. The cell-cell adhesion, 
cell-cell interactions, and extracellular matrix (ECM) of solid tumors forms a physical barrier to 
drug penetration and when combined with the increased distance from blood vessels slows down 
the distribution and movement of chemotherapeutic agents and prevents them achieving effective 
concentrations [24]. The effectiveness of antitumor agents is compromised if the drugs cannot gain 
access to all of the cells in a solid tumor and/or cannot achieve effective concentrations [17, 24, 
25]. 
Although two-dimensional (2D) cell culture models have been used widely in preclinical 
studies for decades, they do not adequately reflect the microenvironment of solid tumors. First, 
one of the most evident differences between 2D and three-dimensional (3D) cell cultures is the 
dissimilarity of morphology and architecture.[26] Cells growing on the flat monolayers can freely 
adhere and spread on the x-y plane, but there is no support for cells in the vertical dimension. 2D 
culture conditions induces a forced apical-basal polarity, which is the main difference between 
epithelial cells and mesenchymal cells.[26]Moreover, tumor cells cultured on 2D flat surfaces do 
not experience the gradients of nutrients, oxygen and waste products that are observed in solid 
tumors.[19] 2D monolayer cell cultures are exposed to a uniform environment and drug 
concentrations that do not mimic the complex and dynamic gradients that exist in solid tumors.[18] 
Limitations to drug penetration in solid tumors has not received sufficient attention in anti-cancer 
drug development. In addition, the gene expression patterns and mutation profiles of tumor cell 
lines can be significantly different to those observed in patient tumors[27, 28], suggesting that cell 
lines may not be totally representative of human cancers. 3D tumor cell models have been 
developed to overcome some of the limitations of 2D cell cultures because they more closely 
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resemble the mechanical and physiological microenvironments of the cells in solid tumors. 
Moreover, drug penetration can be assessed quantitatively in 3D tumor models.[29] Our goal is to 
investigate drug penetration in 2D & 3D HNSCC tumor cell culture models, to determine whether 
differences in drug penetration contributes to the differences in drug responses observed between 
the two culture models. 
1.2 WHY MIGHT 3D TUMOR CELL CULTURES PROVIDE BETTER 
MODELS FOR CANCER DRUG DISCOVERY? 
Although investment in the development of anticancer drugs has increased considerably, <5% 
of potential anticancer drug candidates show sufficient efficacy and safety in clinical trials to be 
approved by the FDA and make it to the market. By contrast, the overall clinical success rate for 
developing new drugs in other therapeutic areas is on average 11%, and reaches 20% for 
cardiovascular diseases.[30] There are several factors that potentially contribute to the limited 
effectiveness of anti-cancer drug development, including insufficient translational research and a 
lack of adequate preclinical models that recapitulate the complexity and molecular heterogeneity 
of cancer. More predictive preclinical models for testing cancer drug efficacy and safety is one 
strategy with potential to significantly improve success rates.[5, 31] 
The overwhelming majority of cell culture studies, including those used for cancer drug 
discovery, are performed in 2D cell cultures grown on surfaces such as micro-well plates and tissue 
culture flasks made from polystyrene or glass. However, it is generally recognized that the flat and 
hard plastic substrates used for 2D cell culture are not representative of either the cellular 
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environment or the adhesive, topographical, and mechanical forces experienced by cells in solid 
tumors.[26, 32] In contrast to tumor cells grown in 2D cultures, 3D tumor cell cultures exhibit 
many aspects of similarity to the cells in solid tumors. 3D tumor cell cultures are compact 
aggregates of tumor cells with increased cell-cell interactions, ECM-to-cell signaling.[33] 
Furthermore, large 3D tumor spheroid structures exhibit a necrotic core surrounded by an inner 
layer of quiescent viable cells and an outer layer of proliferating cells, which more closely 
recapitulates solid tumor architecture and biology to provide better in vitro preclinical models for 
cancer drug discovery than traditional 2D monolayer cell cultures.[34] The structure and 
architecture of 3D tumor cell cultures results in decreasing nutrient concentrations from the 
exterior to the center of the 3D cell mass.[35, 36] Moreover, 3D cell culture models can mimic the 
conditions of insufficient mass transport and limited diffusion in solid tumors, which not only 
produce gradients of O2, nutrients, pH and waste products like CO2[37], but also exhibits decreased 
drug penetration within the 3D tumor cell cultures.[38, 39]  
1.3 WAYS TO FORM 3D SPHEROIDS: 
Three-dimensional tumor spheroid cultures are either anchorage-dependent or anchorage-
independent cell cultures. The scaffolds typically used in anchorage-dependent 3D cell cultures 
include polymeric hard scaffolds, biological scaffolds, and micro-patterned surface 
microplates.[40] A number of biological materials have been used to provide support and mimic 
and/or maintain the microenvironment of cells growth outside of the body, such as poly glycolic 
acid (PGA), poly lactic acid (PLA) and collagen. The scaffolds need to be degradable and nontoxic 
to cells. Whole organism models such as drosophila melanogaster (fruit fly), zebra fish and mouse 
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embryos models have been developed when there is a requirement for tissue-specific 
information.[41] Anchorage independent 3D cell cultures created without the use of scaffolds can 
be generated in hanging drop microplates, microplates coated with ultra-low attachment (ULA) 
surfaces, and in microfluidic devices.[32] 
The wells of ULA microplates have a covalently bonded hydrogel surface that is 
hydrophilic and neutrally charged and effectively prohibits cellular attachment cues.[42] In the 
wells of ULA microplates cell-cell interactions predominate and many tumor cell lines seeded into 
ULA microplates will spontaneously self-assemble to form spheroids at the center of well over 
time. ULA microplates have been used to generate tumor spheroids using variety of different cell 
lines and different cancer types.[43-47] Delyan P. Ivanov et al.[48] developed a brain tumor co-
culture models by means of ULA 96-well plates to assess drug delivery strategies. Toshiyoki 
Tsunoda et al.[49] established 3D culture models to screen drugs targeting KRAS-mediated 
signaling molecules on the ULA plate platforms. Our lab has previously developed a hydrogel 
microwell array method to generate size controlled 3D microtumors spheroids in head and neck 
squamous cell carcinoma (HNSCC) cell lines [50]. We have also developed CellTiter-Glo 
Luminescent (Promega) assays and image acquisition and analysis methods on the ImageXpress 
Micro (IXM) automated imaging platform (Molecular Devices, LLC) to measure and assess 3D 
tumor morphology, cell growth and viability [50]. We applied these methods and others that we 
developed during the course of this thesis project to the research studies described below. 
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1.4 HEAD AND NECK SQUAMOUS CELL CARCINOMA: 
Head and neck squamous cell carcinoma (HNSCC) usually develops in the mucous 
membranes of the mouth, nose, and throat. HNSCC is the 6th most common non-skin cancer in 
the world, and 540,000 new HNSCC cases are diagnosed and 271,000 deaths are reported 
annually.[51] In addition to smoking, alcohol and genetics, human papillomavirus (HPV) 
infections, especially HPV-16, are risk factors for head and neck cancers.[52] The incidence of 
oropharyngeal cancers caused by HPV infection is increasing.[53] The FDA has approved six 
anticancer drugs for HNSCC therapy; methotrexate, 5-fluorouracil, bleomycin, cisplatin, 
docetaxel, and the molecularly targeted agent cetuximab. However, only 25% of HNSCC patients 
respond to these anti-cancer drugs, and despite their introduction, the overall cure rate and 5-year 
survival rate for head and neck cancer has remained at approximately 50% for over 30 years. In 
addition, patients with the recurrent/metastatic HNSCC have a median survival of only 6-12 
months. There is therefore a need for new and effective therapies. Cal33 is a well- characterized 
head and neck cancer cell line model isolated from a squamous cell carcinoma of the tongue. It 
has been widely used in HNSCC cancer research including high-throughput screening[54, 55], 
cytogenetic analysis[56], and for gene mutation and copy number alteration studies[57]. 
1.5 DRUG PENETRATION IN 2D VS. 3D 
Several techniques have been developed to investigate drug penetration in 3D tumor 
spheroids. C. Erlichman et. al. enabled to utilize sequential trypsinization method to test 
cytotoxicity of Adriamycin in MGH-U1 cells grown in monolayer cultures and 3D spheroids[58]. 
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After the compound treatment, the 3D spheroids were trypsinized to cell suspensions and settled 
down again to monolayer cultures, then the colonies were counted using Model-F 
CoulterCounter.[58] Ralph E. Durand utilized hoechst 33342 to stain 3D tumor spheroids in order 
to form a concentration gradient from the outside to the center of the spheroids, and then the single 
cells within the spheroids could be sorted by fluorescence-activated cell sorting techniques[59]. 
This technique was used to selectively recover cells from a given subpopulation based on the 
diffusion gradient of Hoechst staining.  Previous high-content screening studies in our lab have 
observed strong fluorescent signals in images acquired from U2OS cells treated with idarubicin 
and ellipticine in the 1.56–25 μM concentration range.[60, 61] Ellipticine produced strong 
fluorescent signals in the FITC channel and idarubicin produced strong fluorescent signals in the 
Texas red channel.[60] The fluorescent characteristics of these compounds have often been 
quantified and used to identify their localization in cells. [58, 59, 62, 63] 
We selected ellipticine, idarubicin, daunorubicin and doxorubicin as our compound test set 
to measure drug penetration in 2D and 3D HNSCC models because of their fluorescent properties 
within cells. Figure 1  shows the chemical structures of the four compounds. Idarubicin, 
daunorubicin and doxorubicin belong to  the class of anthracycline compounds, which were 
derived from the  bacterium Streptomyces Peucetius.[64] These amphiphilic molecules possess a 
fluorescent hydroxyl-substituted anthraquinone chromophore and a hydrophilic aminoglycosidic 
side chain. The mechanisms of action (MOAs) of anthracycline compounds include (i) 
Intercalation of DNA/RNA for inhibiting DNA/RNA synthesis. (ii) Inhibition of topoisomerase II 
activity. (iii) Generation of free oxygen, leading to damage of DNA, proteins and membranes, 
etc.[65, 66] Anthracyclines are active against a wide variety of hematological and solid tumor 
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malignancies including  acute leukemia, lymphomas, myeloma and neuroblastoma.[67] 
Cardiotoxicity is the major side effect of anthracyclines.[68, 69] 
Ellipticine is a polyaromatic small molecule isolated from apocyanaceae plants, and several 
of its derivatives exhibit significant antitumor and anti-HIV activities (Figure 1).[70] It is a potent 
antineoplastic agent that possesses high efficacy with relatively limited toxicity. Although not all 
of ellipticine’s  MOAs have  been delineated  yet, two prevalent MOAs  include intercalation into 
DNA and inhibition of topoisomerase II[71]. In addition, several studies indicate that the formation 
of covalent DNA adducts mediated  by cytochrome P450 (CYP) oxidized ellipticine metabolites 
and peroxidases might be another MOA of antitumor effects [72]. Previous preclinical trials have 
been undertaken to investigate the antitumor and anti-HIV activities of ellipticine.[73-75] Toxic 
side effects of ellipticine include nausea and vomiting, hypertension, muscular cramp, fatigue, 
mouth dryness, and mycosis of the tongue and esophagus.[76]  
Figure 1 Chemical structures of (A) ellipticine, (B) idarubicin, (C) daunorubicin and (D) doxorubicin. 
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2.0  MATERIALS AND METHODS 
2.1 COMPOUNDS AND REAGENTS 
37% Formaldehyde (Cat. #252549) was purchased from Sigma Aldrich. Hoechst 33342 
(Cat. #H1339) was purchased from Life Technologies. Dimethyl sulfoxide (DMSO) (99.9% high-
performance liquid chromatography-grade) was obtained from Alfa Aesar (Ward Hill, MA). 
Dulbecco’s Mg2+ and Ca2+-free phosphate-buffered saline (PBS) was purchased from Corning 
(Tewksbury, MA). L-glutamine (Cat. # SH30034.01) and Penicillin/Streptomycin (Cat. # 
SH30010) was purchased from Thermo Scientific. Fetal Bovine Serum (Cat. # NC0771932) was 
purchased from Fisher Scientific. CellTiter-Glo® luminescent cell viability assay reagent was 
purchased from Promega. 
Stock solution aliquots of 20mM ellipticine (Tocris Bioscience Cat. #3357), 20mM idarubicin 
(Sigma Aldrich Cat. #H1349), 10 mM daunorubicin (From NCI60 stock, compound #10) and 10 
mM doxorubicin (From NCI60 stock) were prepared in dimethyl sulfoxide (DMSO) and stored at 
-20◦C. Prior to running experiments, the stocks of ellipticine and idarubicin were adjusted to 10 
mM by dilution (1:2) in DMSO.  The 10 mM stock solutions of the four compounds were then 
diluted 1:100 in serum-free DMEM to achieve an intermediate   concentration of 100μM in 1% 
DMSO. For concentration response assays, the four compounds were then added to 2D and 3D 
cell culture assay plates resulting in a 1:4 dilutions and a final top concentration of 25μM and 
0.25% DMSO.  In time course experiments the final compound concentration was 10µm and 0.1% 
DMSO. 
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2.2 CELL CULTURES 
The Cal33 HNSCC cell line was cultured in T75 tissue culture flasks and maintained in medium 
consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% fetal bovine serum (FBS), 
1% L-glutamine, and 1% penicillin/streptomycin (P/S). Cal33 HNSCC cells were passaged every 
2 to 3 days and cultured in an incubator at 37℃ and 5% CO2 and 95% humidity. The FaDu HNSCC 
cell line was cultured in T75 tissue culture flasks and maintained in culture medium consisting of 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 1% non-essential amino acids, 1% L-
glutamine and 1% penicillin/streptomycin (P/S). FaDu HNSCC cells were passaged every 3 to 4 
days and cultured in an incubator at 37℃ in 5% CO2 and 95% humidity. Cell suspensions for 
seeding assay plates were made by dissociating cells from flasks with trypsin, centrifugation of 
dissociated cells at 1200 rpm for 5 minutes at room temperature, and re-suspension in growth 
media.  The number of trypan blue excluding viable cells in the cell suspension was counted using 
a hemocytometer. 
 
2.2.1 Generation of 3D tumor spheroids and 2D cell cultures 
For 3D spheroid generation, 384-well Ultra Low Attachment (ULA) Microplate (Corning 
Cat. # 4516) were rehydrated by adding 50μL of complete media to each well and placement the 
tissue culture incubator for ~0.5h. The rehydration media was removed from the ULA microplates 
and 45μL of the Cal33 cell suspension at different cell densities (625, 1250, 2500, 5000, 10000 
and 20000 cells/well) were seeded into each well using matrix pipette (Thermo Scientific Inc.). 
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384-well ULA microplates containing cell suspensions were then centrifuged at 100 rpm for 1 
minute. After the centrifugation, 3D HNSCC spheroids formed spontaneously over time when the 
plates were placed in incubator at 37℃ and 5% CO2 and 95% humidity. 
For 2D cell culture assay plates, 45μL of the desired densities of Cal33 cell suspension 
were seeded into 384-well tissue culture treated microplates (Greiner Cat. # 781091). The 384-
well plates were centrifuged at 100 rpm for 1 minute and incubated overnight at 37℃ and 5% CO2 
and 95% humidity. 
2.3 2D&3D HNSCC GROWTH INHIBITORY 50 CONCENTRATION (GI50) 
ASSAY 
For HNSCC cell line GI50 assays, Cal33 cells were harvested, counted, and seeded into an 
uncoated, white, opaque 384-well assay plate for 2D assays (Greiner Bio-one Cat # 781080) or 
into ULA 384-well assay plate for 3D assays on day 1. For 2D assays, Cal33 cells were seeded at 
1,000 cells per well in 45μL of tissue culture media into the wells of the 384-well assay plates, and 
for 3D assays Cal33 cells were seed at 5,000 cells per well in 45μL of tissue culture media into the 
wells of ULA 384-well microplates. The plates were then cultured overnight at 37℃, 5% CO2, 
and 95% humidity. On day 2, 5μL of 4 compounds (ellipticine, idarubicin, daunorubicin and 
doxorubicin) at the indicated concentrations in serum-free media were transferred into the test 
wells of the 2D and 3D assay plates on the Janus MDT automated liquid handler equipped with a 
384-well transfer head. Also, 5μL of 5% DMSO and 5μL of 2mM doxorubicin were added to the 
minimum and maximum control wells (n=32 each). The compound-treated plates were then 
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cultured for 72 h in an incubator at 37℃, 5% CO2, and 95% humidity. We used the Cell-Titer 
Glo® (CTG) reagent which generates a luminescent signal (RLUs) that is directly proportional to 
the concentration of ATP ([ATP]) released by viable cells lysed in detergent to measure cell growth 
and viability (insert Johnston et al, STAT3 AD & HCS manuscript references- earlier).  On day 5, 
25μL of the Cell-Titer Glo® (CTG) cell viability detection reagent was dispensed into compound 
and control wells of 2D and 3D assay plates using a matrix pipette, and the plates were incubated 
for 15 min. The luminescence signals were then captured on the M5e micro-titer plate reader 
platform. For the HNSCC GI50 assays, we used the DMSO and Doxorubicin control data from 2D 
and 3D microplates to normalize the growth inhibition of each compound and expressed it as 
percentage of controls. The DMSO and 200μM doxorubicin controls were used to calculate the S: 
B ratios and Z’-factor coefficient statistics for the assay signal windows.  
2.4 DRUG PENETRATION CONCENTRATION-RESPONSE, TIME-
COURSE AND SEEDING DENSITY ASSAYS 
The penetration of ellipticine, idarubicin, daunorubicin and doxorubicin into HNSCC tumor 
cells in 2D cultures and 3D tumor spheroids were investigated at different drug concentrations, 
compound exposure times, and cell seeding densities.  
In concentration response assays, 5μL of serial dilutions of the four compounds were added 
to replicate (n=3) wells of the 2D and 3D assay plates. The final concentrations of the test 
compounds in the wells were 25, 12.5, 6.25, 3.125, 1.5625 and 0.78125μM. After a 15 min 
incubation at 37℃, 5% CO2, and 95% humidity, the 2D and 3D ULA microplates were then fixed 
and stained with Hoechst by the addition of 50μL of fixative solution to each well and a 30 min 
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incubation at room temperature in the dark. The fixative solution was prepared in PBS, and 
contained 37% Formaldehyde and Hoechst 33342 in a ratio of 400:100:1. The compounds, media 
and fixative mixture was aspirated using the Janus MDT automated liquid handler and the plates 
were washed 3 times with PBS.  50μL of PBS was then added to each well after washing and the 
plates were then sealed with aluminum foil. 2D and 3D assay plates were imaged and analyzed on 
the IXM automated high-content imaging platform as described below.  
In time-course assays, 5μL of the four test compounds (10μM final) were transferred into 
replicate (n=3) wells and incubated at 37℃, 5% CO2, and 95% humidity for the indicated time 
periods: 0, 2.5, 5, 10, 15, 30 and 45 min. The 2D and 3D assay plates were fixed, stained with 
Hoechst, and washed as described above, and then imaged and analyzed on the IXM automated 
high-content imaging platform as described below.  
In cell density assays, Cal33 and FADU HNSCC cell lines were seeded into 384-well 2D and 
3D assay plates, at seeding densities of 625, 1,250, 2,500, 5,000, 10,000 and 20,000 cells per well.  
5μL of the four compounds (10μM final) were added to replicate (n=3) wells and incubated at 
37℃, 5% CO2 and 95% humidity for 15 minutes. The 2D and 3D assay plates were fixed, stained 
with Hoechst, and washed as described above, and the plates were then imaged and analyzed on 
the IXM automated high-content imaging platform as described below.  
2.5 IMAGE ACQUISITION 
The ImageXpress® Micro (IXM) XLS System is a wide-field automated high-content 
imaging platform (Molecular Devices, LLC) capable transmitted light, and fluorescent imaging of 
fixed- or live-cell assays, tissues and small organisms. Combined with the MetaXpress image 
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analysis software, it can both acquire and analyze images. The IXM high-content analysis system 
consists of a 1.4 megapixel cooled CCD camera (standard model). The IXM has a transmitted light 
module and is equipped with the following ZPS filter sets for fluorescent imaging: DAPI, 
FITC/ALEXA 488, CY3 (TRITC), CY5, and Texas Red. Images of Cal33 microtumors were 
acquired using either a 4x or 10x objective in both the transmitted light and fluorescent acquisition 
modes. The infrared laser autofocus was used to detect the bottom of the plate and well, and then 
a series of 10-20 Z-stack images were acquired, each separated by a step size of 20µm in a range 
equally distributed above and below a set Z-position. A journal was then used to collapse all of the 
images in the Z-stack to generate a single maximum projection image.  
 
2.6 MULTI-WAVELENGTH CELL SCORING (MWCS) 
We used the multi-wavelength cell scoring (MWCS) image analysis module to quantify 
the integrated fluorescent intensities of the 4 compounds in the digital images of the 2D and 3D 
HNSCC cultures acquired on the IXM as described above.  
The MWCS module image segmentation identified and classified Hoechst 33342 stained 
fluorescent objects in Ch1 that exhibited appropriate fluorescent intensities above background and 
size (width, length, and area) characteristics of Cal33 nuclei and used these objects to create 
nuclear masks for each cell.  For 2D Cal33 cell cultures we defined the approximate minimum 
width of Hoechst stained nuclei to be 8 µm and the approximate maximum width to be 30 µm, and 
the threshold intensity above local background to be 5 (Figure 2).  
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After applying user defined background average intensity thresholds, typically 200 in both 
Ch2 (FITC) and Ch3 (TRITC), the MWCS module image segmentation then creates cell masks 
for each cell. The nuclear mask from Ch1 was then used to quantify the integrated fluorescence 
intensity of Hoechst within the nuclear region of Cal33 cells and also to count the number of cells 
per image.  The derived Cal33 cell masks from Ch2 and Ch3 were then used to quantify the 
integrated fluorescence intensity of the compounds in the FITC (Ch2) and TRITC (Ch3) channels 
(Figure 2).  The MWCS image analysis module outputs quantitative data including: The W1 mean 
stain integrated fluorescent intensities of the Hoechst stained objects (compartments) in Ch1; the 
number of compartments or total cell count in Ch1; the W2 and W3 mean stain integrated 
fluorescent intensities of the Ch2 and Ch3 signals in whole cells.  Positive W1/W2/W3 Mean Stain 
Integrated Intensity is the total pixel intensity of the W1/W2/W3 stain over the stained area in 
W1/W2/W3 positive cells, divided by the number of cells positive for W1/W2/W3. 
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Figure 2 2D Cal33 Cultures: MWCS Nuclear & cellular Masks. Fluorescent images of Cal33 cells in 2D cell 
cultures ± 12.5 µM idarubicin in (A)Ch1 Hoechst; (B) Ch2 FITC and (C) Ch3 TRITC.  
 
Normal tissue culture microplates were seeded by 1000 Cal33 HNSCC cells per well as previously described. 
5μL of idarubicin were added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 The 
2D microplate was fixed and stained in 3.7% formaldehyde containing Hoechst-33342. The 2D microplates were 
washed by PBS for three times after the 45-min fixation. Images were then acquired on the IXM High-Content Analysis 
System and analyzed using the MWCS image analysis module. The images presented are representative of similar 
images obtained in at least 3 independent experiments.   
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For 3D Cal33 or FADU spheroids we defined the approximate minimum width of Hoechst 
stained nuclei in the whole spheroid to be 150 µm and the approximate maximum width to be 550 
µm, and the threshold intensity above local background to be 70 (Figure 3). After applying user 
defined background average intensity thresholds, typically 50-70 in both Ch2 (FITC) and Ch3 
(TRITC), the MWCS module image segmentation then created masks for each spheroid. The 
spheroid mask from Ch1 was used to quantify the integrated fluorescence intensity of Hoechst 
within the Cal33 spheroid and to count the number of spheroids per image (Figure 3).  The derived 
Cal33 spheroid masks from Ch2 and Ch3 were used to quantify the integrated fluorescence 
intensity of the compounds in the FITC (Ch2) and TRITC (Ch3) channels (Figure 3).  The MWCS 
image analysis module outputs quantitative data including: The W1 mean stain integrated 
fluorescent intensities of the Hoechst stained spheroids in Ch1; the number of spheroids in Ch1; 
the W2 and W3 mean stain integrated fluorescent intensities of the Ch2 and Ch3 signals in the 
spheroids.  
 
 
2.7 DATA PROCESSING AND CURVE FITTING 
For the HNSCC growth inhibition GI50 assays, we used the DMSO control wells (Max 
controls n=32) to represent uninhibited growth and 200μM Doxorubicin control wells (Min 
controls, n=32) to represent 100% of tumor cell cytotoxicity respectively. We then used the mean 
maximum and minimum plate controls to normalize the data from the compound treated wells as 
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% of controls. Also, the DMSO and 200μM Doxorubicin control wells were used to calculate 
signal: background ratios and Z’-factor coefficient assay performance statistics for the growth 
inhibition assay signal windows.  GI50 curves were fitted in a non-linear sigmoidal log(inhibitor) 
vs. normalized response model –using the variable slope equation in the GraphPad Prism 6 
software: Y=100/(1+10^((LogIC50-X) *Hillslope))), where y was the percent inhibition and x was 
the corresponding log10 of the compound concentration. The GI50 is the concentration of compound 
that gives a 50% response, half way between 0% and 100%.  The Hillslope describes the steepness 
of the curve. 
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Figure 3 3D Cal33 Cultures: MWCS Spheroid Masks. Fluorescent images of Cal33 cells in 3D tumor spheroids + 
12.5 µM idarubicin in (A)Ch1 Hoechst; (B) Ch2 FITC and (C) Ch3 TRITC.  
 
384-well ULA microplates were seeded by 5000 cells per well of Cal33 HNSCC cells. 5μL of idarubicin were 
added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 The 2D microplate was fixed 
and stained in 3.7% formaldehyde containing Hoechst-33342. The ULA microplates were washed by PBS for three 
times after the 45-min fixation. Images were then acquired on the IXM High-Content Analysis System and analyzed 
using MWCS image analysis module. The images are presented are representative of similar images obtained in at 
least 3 independent experiments. 
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3.0  RESULTS AND DISCUSSION 
3.1 2D & 3D HNSCC GROWTH INHIBITORY 50 CONCENTRATION (GI50) 
To determine and compare the growth inhibitory actions of ellipticine, idarubicin, 
daunorubicin and doxorubicin in 2D and 3D HNSCC cell cultures, the Cell Titer Glo® (CTG, 
Promega) detection assay was utilized to measure cell growth and viability in 2D and 3D HNSCC 
cultures. We began with the 2D CTG HNSCC growth inhibition assays that our lab has established 
previously[54, 55] and conducted experiments to determine if those methods could be transferred 
into 384-well ULA microplates to measure 3D HNSCC spheroid growth and viability. The CTG 
luminescent cell viability assay is a homogeneous method of determining the number of viable 
cells based on the quantification of ATP present, which is directly proportional to the number of 
cells in cultures[77]. Cal33 HNSCC cells that had been seeded into 384-well ULA microplates in 
serum-containing medium at the indicated cell densities were cultured overnight in an incubator. 
The cells were then stained with the live cell reagent Calcein AM and the dead cell reagent 
ethidium homodimer-1, then fixed in 3.7% formaldehyde containing Hoechst-33342. The 
Hoechst-33342 DNA dye was utilized to stain the nuclei of the Cal33 cells. Calcein AM is a cell 
permeant dye that can stain live cells. The non-fluorescent Calcein AM is converted to a green-
fluorescent calcein after the acetoxymethyl ester hydrolysis by intracellular esterase. Ethidium 
homodimer-1 (EthD-1) can be used to detect dead cells by binding to DNA and emit red 
fluorescence when the membrane is disrupted in dead cells, Ethidium homodimer is impermeable 
to the intact membrane of live cells, it can only stain the DNA of dead cells with disrupted plasma 
membranes. We then utilized the IXM automated imaging platform to sequentially acquire images 
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for transmitted light along with the Hoechst (Ch 1), FITC (Ch 2) and Texas Red (Ch 3) fluorescent 
channels. The transmitted light and fluorescent images of Hoechst-stained indicated that the size 
of 3D tumor spheroids increased when more cell were seeded into the 384-well ULA microplates 
(Figure 4). Fluorescent images of Cal33 HNSCC cells stained with calcein AM and EthD-1 
indicated that the vast majority of the Cal33 cells in the 3D tumor spheroids formed were alive 
after the 24-hour incubation period (Figure 4).  The color composite overlays of the Ch1, Ch 2 and 
Ch 3 fluorescent images also indicates that the majority of Cal33 cells in different sized 3D tumor 
spheroids are viable and only a few dead cells stained by EthD-1 were apparent in the core of the 
3D tumor spheroids. These images demonstrate that Cal33 cells seeded in ULA plates 
spontaneously form 3D tumor spheroids when they are deprived of cell attachment cues and 
because the cells remain viable under these conditions they should be amenable to the development 
of 3D tumor model growth inhibition assays (Figure 4). 
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Figure 4 Generation of size-controlled 3D Cal33 HNSCC spheroids. (A) fluorescent images of Hoechst stained in 
Ch 1, calcein AM stained in Ch 2, ethidium homodimer-1 stained in Ch 3 and color composite of three fluorescent 
channels. 
 
Cal33 HNSCC cells were seeded in 3D 384-well ULA microplates with a serial seeding density of 1250, 2500, 5000, 
10000 and 20000 cells per well. Live–dead staining by calcein AM and ethidium homodimer -1 was added after 24 
hours, which indicated the cell viability in 3D spheroids. Images of transmitted light, ch-1 hoechst, ch-2 FITC, ch-3 
Texas Red and color combined were captured on ImageXpress Micro (IXM) automated imaging system. The images 
presented are representative of similar images obtained in 3 independent experiments. 
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To determine if our 2D CTG assay would be transferable to our 3D Cal33 spheroids formed 
in ULA microplates we added the CTG reagent to Cal33 HNSCC spheroids formed at the indicated 
cell seeding densities after 24-hours in culture.  Figure 5  demonstrates that the relative luminescent 
units (RLU’s) increased in a linear fashion in spheroids formed by 625 up to 5000 cells per well 
(Figure 5), and although the RLU’s continue to increase thereafter with more cells added, the rate 
of increase was no longer linear with respect to cell number. The data represent the mean ± SD of 
triplicates and the experiments were repeated independently on at least 3 occasions. Based on these 
data, we selected 5000 cells per well as a suitable cell seeding density for the 3D HNSCC growth 
inhibition GI50 assays. 
 
To define the assay signal window or dynamic range of the 2D and 3D HNSCC growth 
inhibition assays, we used the 0.5% DMSO control wells to represent uninhibited growth (Max 
controls n=32), and 200μM Doxorubicin + 0.5% DMSO control wells to represent 100% of tumor 
cell cytotoxicity (Min controls, n=32) respectively (Figure 6). We also used the DMSO and 200μM 
Doxorubicin control wells to calculate signal: background ratios and Z’-factor coefficient 
performance statistics for the 2D (Figure 6) and 3D (Figure 6) growth inhibition assays. In 
addition, we used the mean maximum and minimum plate controls to normalize the data from 
compound treated wells as % of controls.  Figure 6 indicates  that the 2D and 3D HNSCC  assay 
plate controls exhibited a robust and reproducible separation between the 200µM doxorubicin 
responses and 0.5% DMSO signals. In Cal33 HNSCC 2D cultures and 3D tumor spheroids, the 
S:B ratios were 223.6-fold  and 22.1-fold, respectively. The Z’-factor coefficients for the 2D  and 
3D HNSCC growth inhibition assays were 0.45 and 0.51, respectively (Figure 6). These data 
indicate that the plate controls for the 2D  and 3D HNSCC growth inhibition  assays performed 
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very well and provide a robust and reporducible dynamic range in which to measure the effects of 
compounds.    
Figure 5 CellTiter-Glo (CTG) cell viability assay on 3D 384-well ULA microplate. 
 
CellTiter-Glo (CTG) detection reagent was added to quantify the cellular ATP levels in order to measure 
viable cells numbers. 25 µL of CellTiter-Glo reagent was added to each well. The plate was then incubated on a 
shaking platform for 15 min at room temperature. Relative luminescence (RLUs) units were captured using a 
SpectraMax M5e Multi- Mode Microplate Reader (Molecular Devices, LLC). The data represent the mean ± SD (n 
=3) of triplicates determinations from one of three independent experiments. 
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Figure 6 Signal to background ratios (S: B) and z’- factor of (A)2D cultures & (B) 3D ULA micro plates.   
 
 DMSO and 200µM doxorubicin controls were used to calculate the signal: background ratios and Z’-factor 
coefficient statistics for the assay signal window. S: B ratio = Mean of DMSO controls/ Mean of 2mM doxorubicin. 
Z’-factor = 1- ((3*(SD of 2mM doxorubicin + SD of DMSO controls))/ (Mean of DMSO controls – 2mM doxorubicin). 
Each of DMSO and 2mM doxorubicin controls were repeated in 32 wells. 
 
 
Based on these data, we proceeded to evaluate and compare the ability of ellipticine, 
idarubicin, daunorubicin and doxorubicin to inhibit the growth of  Cal33 HNSCC cells in 2D and 
3D cell cultures (Figure 7 &  
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Table 1). Cal33 spheroids were significantly (>5-fold) more resistant than the 
corresponding 2D Cal33 cultures to growth inhibition by all four cancer drugs (Figure 7).  
Table 1 GI50 values of ellipticine, idarubicin, daunorubicin and doxorubicin in 2D and 
3D cell cultures. lists the individual and mean GI50 values for ellipticine, idarubicin, daunorubicin, 
and doxorubicin in 2D and 3D culture models that were obtained in three independent growth 
inhibition experiments. After excluding two apparent 3D GI50 outlier values from experiment 1 ( 
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Table 1, highlighted in orange), the 3D:2D GI50 ratios for ellipticine, idarubicin, 
daunorubicin, and doxorubicin were 6.6-fold, 22.3-fold, 7.2-fold and 10.3-fold respectively, 
indicating that Cal33 spheroids were significantly more resistant to growth inhibition than 2D 
cultures. There are several factors that could contribute to the enhanced drug resistance of  3D 
HNSCC spheroids. Reduced penetration of drugs into cells in different regions or zones of 3D 
spheroid cultures (surface layers, intermediate layers, and interior core) might lead to  non-uniform 
drug exposure levels in cells in these different regions such that compounds might fail to achieve 
efficacious concentrations [37]. All four compounds are toposiomerase II inhibitors that induce 
apoptosis in proliferating tumor cells by inhibiting the DNA synthesis[65, 66]. Cells in different 
regions of 3D spheroids exhibit differential rates of cellular proliferation such that the cells that 
are in quiescent (intermediate layers) or dormant (interior core) zones might be less sensitive to 
the effects of antiproliferative agents[34]. The necrotic core and the inner layers of quiescent viable 
cells inside 3D spheroids might revert to proliferating cells if the outer layer of actively 
proliferating cells are killed by antitumor conpounds[34]. To investigate whether the increased 
resistance of 3D HNSCC spheroids to growth inhibition by ellipticine, idarubicin, daunorubicin, 
and doxorubicin might be due to differences in drug penetration between 2D and 3D HNSCC 
cultures, we conducted a series of experiments to define the concentration, time, and cell density 
dependent penetration of these compounds in 2D and 3D cell culture models. 
 
Figure 7 2D &3D Cal33 HNSCC GI50 assays.  GI50 assay on 2D cell cultures and 3D tumor spheroids treated 
with (A) Ellipticine; (B) Idarubicin; (C) Daunorubicin; (D) Doxorubicin. 
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1000 Cal33 HNSCC cells were seeded into 2D 384-well assay plates and 5000 Cal33 HNSCC cells were 
seeded into 3D 384-well ULA microplates, incubated at 37℃, 5% CO2, and 95% humidity. After 24 hours, indicated 
concentration of compounds was transferred by Janus MDT automated liquid handler into the testing wells of 2D and 
3D plates. Controls well received DMSO and 2mM doxorubicin respectively and the plates were incubated for 
additional 72 hours. On day 5, 25μL of the CellTiter Glo (CTG) cell viability detection reagent was dispensed into 
compound wells of 2D and 3D microplates by matrix pipette. The plates were then incubated on a shaking platform 
for 15 min at room temperature. Relative luminescence (RLUs) units were captured using a SpectraMax M5e Multi- 
Mode Microplate Reader (Molecular Devices, LLC). For the 2D & 3D HNSCC IC50 assays, DMSO controls were 
used to normalize as 0% and 2mM doxorubicin was used to normalize as 100% inhibition. The data represent the 
mean ± SD (n=3) of triplicates determination from one of 3 independent experiments. 
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Table 1 GI50 values of ellipticine, idarubicin, daunorubicin and doxorubicin in 2D and 3D cell cultures. 
  GI50 data of 2D and 3D GI50 assays presented in table was generated in three independent experiments. 
Each of the maximum (200µM doxorubicin) and minimum (0.5% DMSO) plate controls conducted on the same assay 
microplates. The present the mean ± SD (n=3) of triplicates of these three independent experiments. 
 
3.2 ABSORPTION AND EMISSION SPECTRUM OF COMPOUNDS IN 
SOLUTION 
Fluorescent molecules absorb radiation at specific wavelengths to reach excited states and 
after energy is dissipated by the system, the molecule releases energy as a longer wavelength 
fluorescence emission. To determine the optimal excitation (Ex) and emission (Em) wavelengths 
of ellipticine, idarubicin, daunorubicin and doxorubicin, we dissolved the compounds in PBS and 
performed 10 nm wavelength scans to measure their absorption and emission spectra on the M5e 
plate reader. The absorption spectra of the 4 compounds dissolved in PBS at 25µM were measured 
to select a suitable excitation wavelength for each compound (Figure 8, Figure 9, Figure 10 & 
Figure 11). The three structurally related anthracycline compounds idarubicin, daunorubicin and 
doxorubicin (Figure 1) had very similar absorption spectra with a broad absorption peak between 
400 and 550 nm (Figure 8, Figure 9 & Figure 10). In contrast, ellipticine did not exhibit an obvious 
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absorption peak between 350 and 750 nm (Figure 11).  Based on the absorption spectra of 
idarubicin, daunorubicin and doxorubicin we selected an Ex wavelength of 480 nm to perform a 
10nm fluorescence emission spectral scan for these compounds (Figure 8, Figure 9 & Figure 10).  
When excited at 480 nm all three structurally related anthracycline compounds idarubicin, 
daunorubicin and doxorubicin (Figure 1) produced very similar emission spectra with a broad 
emission peak between 520 and 650 nm (Figure 8, Figure 9 & Figure 10). Consistent with its lack 
of absorption at 480 nm, ellipticine failed to produce a fluorescent emission spectrum when excited 
at 480 nm (Figure 11). The relative fluorescent intensity values (RFUs) of idarubicin (Ex 480, Em 
570 nm), daunorubicin (Ex 480, Em 590 nm), and doxorubicin (Ex 480, Em 590 nm) increased 
linearly with respect to compound concentration (Figure 8, Figure 9 & Figure 10). In contrast, the 
relative fluorescent intensity values (RFUs) of ellipticine (Ex 480, Em 590 nm) were zero at all 
concentrations (Figure 11). Based on the linear relationship between the fluorescent intensity 
RFUs produced by idarubicin, daunorubicin and doxorubicin and their concentrations in solution, 
we conclude that the fluorescent intensity values of these 3 compounds can be used to infer the 
relative concentrations of these drugs within cells. 
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Figure 8 Idarubicin (A) Absorption spectrum of 20µM idarubicin in PBS; (B) Fluorescent emission spectrum of 
20µM idarubicin in PBS Ex. 480 nM; (C) Fluorescent intensity of different concentrations of idarubicin in PBS, 
Ex 480 nm & Em. 570 nm. 
 
(A) 20µM of idarubicin was added to the wells of a 384-well assay microplate in 50µL PBS per well, and the 
absorption spectrum was acquired on a SpectraMax® M5e multi-mode microplate reader. (B) Using an excitation 
wavelength of 480 nm the fluorescence emission spectrum was then acquired on the M5e. (C) The relative fluorescence 
intensity units (RFU’s) of 25, 12.5, 6.25, 3.125, 1.5625 and 0.78125μM daunorubicin at Ex. 480 nm and Em 570 nm 
was then acquired on the M5e. There were three replicate wells (n=3) for each idarubicin concentration and the mean 
RFU’s ± SD of the triplicates are presented. 
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Figure 9 Daunorubicin (A) Absorption spectrum of 20µM daunorubicin in PBS; (B) Fluorescent emission 
spectrum of 20µM daunorubicin in PBS Ex. 480 nM; (C) Fluorescent intensity of different concentrations of 
daunorubicin in PBS, Ex 480 nm & Em. 590 nm. 
 
(A) 20µM of daunorubicin was added to the wells of a 384-well assay microplate in 50µL PBS per well, and the 
absorption spectrum was acquired on a SpectraMax® M5e multi-mode microplate reader. (B) Using an excitation 
wavelength of 480 nm the fluorescence emission spectrum was then acquired on the M5e. (C) The relative fluorescence 
intensity units (RFU’s) of 25, 12.5, 6.25, 3.125, 1.5625 and 0.78125μM daunorubicin at Ex. 480 nm and Em 590 nm 
was then acquired on the M5e. There were three replicate wells (n=3) for each daunorubicin concentration and the 
mean RFU’s ± SD of the triplicates are presented. 
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Figure 10 Doxorubicin (A) Absorption spectrum of 20µM doxorubicin in PBS; (B) Fluorescent emission spectrum 
of 20µM doxorubicin in PBS Ex. 480 nM; (C) Fluorescent intensity of different concentrations of doxorubicin in 
PBS, Ex 480 nm & Em. 590 nm. 
 
(A) 20µM of doxorubicin was added to the wells of a 384-well assay microplate in 50µL PBS per well, and the 
absorption spectrum was acquired on a SpectraMax® M5e multi-mode microplate reader. (B) Using an excitation 
wavelength of 480 nm the fluorescence emission spectrum was then acquired on the M5e. (C) The relative fluorescence 
intensity units (RFU’s) of 25, 12.5, 6.25, 3.125, 1.5625 and 0.78125μM doxorubicin at Ex. 480 nm and Em 590 nm 
was then acquired on the M5e. There were three replicate wells (n=3) for each doxorubicin concentration and the 
mean RFU’s ± SD of the triplicates are presented. 
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Figure 11 Ellipticine (A) Absorption spectrum of 20µM ellipticine in PBS; (B) Fluorescent emission spectrum of 
20µM ellipticine in PBS Ex. 480 nM; (C) Fluorescent intensity of different concentrations of ellipticine in PBS, 
Ex 480 nm & Em. 570 nm. 
 
(A) 20µM of ellipticine was added to the wells of a 384-well assay microplate in 50µL PBS per well, and the absorption 
spectrum was acquired on a SpectraMax® M5e multi-mode microplate reader. (B) Using an excitation wavelength of 
480 nm the fluorescence emission spectrum was then acquired on the M5e. (C) The relative fluorescence intensity 
units (RFU’s) of 25, 12.5, 6.25, 3.125, 1.5625 and 0.78125μM ellipticine at Ex. 480 nm and Em 570 nm was then 
acquired on the M5e. There were three replicate wells (n=3) for each ellipticine concentration and the mean RFU’s 
± SD of the triplicates are presented. 
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3.3 COMPOUND PENETRATION IN 2D AND 3D CAL33 HNSCC CELL 
CULTURE MODELS 
3.3.1 IMAGES AND CONCENTRATION DEPENTENT PENETRATION OF 2D AND 3D 
CULTURES 
We first investigated the concentration dependent penetration of ellipticine, idarubicin, 
daunorubicin and doxorubicin into 2D Cal33 cell cultures. Cal33 cells that had been seeded into 
normal tissue culture assay plates were cultured overnight and then exposed to the indicated 
concentrations of the 4 compounds for 15-min. The 2D cell cultures were then fixed in 3.7% 
formaldehyde containing Hoechst-33342 for 45 min, and then washed by repeated aspiration and 
rinsing with PBS. We then utilized the IXM automated imaging system to acquire images 
sequentially in Ch 1 Hoechst (blue), Ch 2 FITC (green) and Ch 3 TRITC (red) fluorescent 
channels. Hoechst 33342 DNA staining in Ch 1 was used to identify the nuclei of Cal33 cells in 
2D cell cultures. The color composite overlays of the Ch 1, Ch 2 and Ch 3 fluorescent images of 
Hoechst stained nuclei are predominantly blue, which indicates that the Hoechst staining only 
fluoresces in Ch 1 (Figure 12).  
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Figure 12  Grayscale and color composite images of 2D Cal33 HNSCC cells stained with Hoechst 33342. (A) 
Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale images of idarubicin-treated (Ch 2, Ch 3) and 
color composite images of Ch 1, Ch 2 and Ch 3 Cal33 HNSCC cells. 
 
Normal tissue culture microplates were seeded by 1000 Cal33 HNSCC cells per well as previously described. 
The 2D microplate was fixed and stained in 3.7% formaldehyde containing Hoechst- and then washed by repeated 
aspiration and rinsing with PBS after the 45-min fixation. Images were then acquired on the IXM High-Content 
Analysis System and analyzed using the MWCS image analysis module. The images presented are representative of 
similar images obtained in at least 3 independent experiments.   
 
 
 
 
 Fluorescent images in Ch2 (FITC) and Ch3 (TRITC) of 2D Cal33 cell cultures exposed to 
idarubicin produced strong fluorescent signals, and the color composite images showed a 
combination of blue (Hoechst staining), together with strong green and red signals that was 
predominantly yellow (Figure 13).  
A Ch-1 hoechst Color composite
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Figure 13  Grayscale and color composite images of 2D Cal33 HNSCC cells + idarubicin treatment. (A) Greyscale 
images of Hoechst 33342-stained nuclei (Ch 1), greyscale images of idarubicin-treated (Ch 2, Ch 3) and color 
composite images of Ch 1, Ch 2 and Ch 3 Cal33 HNSCC cells. 
 
Normal tissue culture microplates were seeded by 1000 Cal33 HNSCC cells per well as previously described. 
5μL of idarubicin were added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 The 
2D microplate was fixed and stained in 3.7% formaldehyde containing Hoechst-33342. The 2D microplates were 
Ch-1 hoechst
Color composite
Ch-2 FITC
Ch-3 TRITC
A
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washed by PBS for three times after the 45-min fixation. Images were then acquired on the IXM High-Content Analysis 
System and analyzed using the MWCS image analysis module. The images presented are representative of similar 
images obtained in at least 3 independent experiments.   
 
 
The images indicate that idarubicin fluorescence can be detected in 2D Cal33 cells in both 
the green (Ch 2) and red (Ch 3) channels and that the Hoechst fluorescent signal (Ch1) appeared 
to be significantly less intense than in cells that were not exposed to compounds (Compare Figure 
13 to Figure 12). Daunorubicin and doxorubicin-exposed cells were also fluorescent in the images 
from the green (Ch 2) and red (Ch 3) channels but the red signal predominates making the color 
composite image purple due to the blue (Hoechst staining) and strong red signal (Figure 14 & 
Figure 15). The Hoechst fluorescent signal (Ch1) appeared to be significantly less intense in 2D 
Cal33 cells that were exposed to daunorubicin and doxorubicin compared to cells that were not 
exposed to compounds (Compare Figure 14 & Figure 15 to Figure 12).  
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Figure 14 Grayscale and color composite images of 2D Cal33 HNSCC cells + daunorubicin treatment. (A) 
Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale images of daunorubicin-treated (Ch 2, Ch 3) 
and color composite images of Ch 1, Ch 2 and Ch 3 Cal33 HNSCC cells. 
 
Normal tissue culture microplates were seeded by 1000 Cal33 HNSCC cells per well as previously described. 
5μL of daunorubicin were added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 
The 2D microplate was fixed and stained in 3.7% formaldehyde containing Hoechst-33342. The 2D microplates were 
washed by PBS for three times after the 45-min fixation. Images were then acquired on the IXM High-Content Analysis 
System and analyzed using the MWCS image analysis module. The images presented are representative of similar 
images obtained in at least 3 independent experiments.   
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Figure 15 Grayscale and color composite images of 2D Cal33 HNSCC cells + doxorubicin treatment. (A) Greyscale 
images of Hoechst 33342-stained nuclei (Ch 1), greyscale images of doxorubicin-treated (Ch 2, Ch 3) and color 
composite images of Ch 1, Ch 2 and Ch 3 Cal33 HNSCC cells. 
 
Normal tissue culture microplates were seeded by 1000 Cal33 HNSCC cells per well as previously described. 
5μL of doxorubicin were added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 The 
2D microplate was fixed and stained in 3.7% formaldehyde containing Hoechst-33342. The 2D microplates were 
washed by PBS for three times after the 45-min fixation. Images were then acquired on the IXM High-Content Analysis 
System and analyzed using the MWCS image analysis module. The images presented are representative of similar 
images obtained in at least 3 independent experiments.   
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 In addition to inhibition of topoisomerase II activity, the anthracycline compounds 
intercalate with DNA/RNA and it may be that they compete with Hoechst for the same DNA 
binding sites and thereby reduce the Hoechst fluorescent signal relative to cells that were not 
exposed to compounds. For idarubicin, daunorubicin and doxorubicin the location of the 
fluorescent signal is predominantly nuclear, although idarubicin also appears to have a strong 
perinuclear distribution (Figure 13, Figure 14 & Figure 15)  
Interestingly, although the fluorescence of ellipticine cannot be detected directly when 
dissolved in PBS, the compound has previously been shown to be fluorescent within cells[60, 61]  
(Figure 16). It may be that ellipticine becomes fluorescent after it intercalates with DNA or 
ellipticine-DNA adducts are formed. Fluorescent images of 2D Cal33 exposed to ellipticine 
exhibited strong fluorescent signals in the green channel (Ch2, FITC), and the color composite 
images showed a combination of blue (Hoechst staining) together with a strong green signal 
(Figure 16).  Interestingly the ellipticine fluorescence was located throughout the cells and the 
Hoechst-33342 stained DNA images were similar to cells not exposed to compounds (Compare 
Figure 16 to Figure 12). 
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Figure 16 Grayscale and color composite images of 2D Cal33 HNSCC cells + ellipticine treatment. (A) Greyscale 
images of Hoechst 33342-stained nuclei (Ch 1), greyscale images of ellipticine-treated (Ch 2) and color composite 
images of Ch 1 and Ch 2 Cal33 HNSCC cells. 
 
Normal tissue culture microplates were seeded by 1000 Cal33 HNSCC cells per well as previously described. 
5μL of ellipticine were added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 The 
2D microplate was fixed and stained in 3.7% formaldehyde containing Hoechst-33342. The 2D microplates were 
washed by PBS for three times after the 45-min fixation. Images were then acquired on the IXM High-Content Analysis 
System and analyzed using the MWCS image analysis module. The images presented are representative of similar 
images obtained in at least 3 independent experiments.   
 
 To extract and analyze quantitative data from the digital images, we utilized the 
multi-wavelength cell scoring (MWCS) image analysis module of the MetaXpress software on the 
IXM platform. The algorithm uses the Hoechst DNA stain to identify cell nuclei, create a nuclear 
mask, and count cells. The algorithm then uses the nuclear mask and user set thresholds in the 
FITC (Ch2, green) and TRITC (Ch3, red) channels to create a cell mask and outputs the average 
and integrated fluorescent intensity signals from within the cell masks. Figure 17 portrays the 
Ch-1 hoechst Color compositeCh-2 FITCA
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integrated fluorescent intensity measurements obtained in 2D Cal33 cell cultures exposed to the 
indicated concentrations of ellipticine, idarubicin, daunorubicin, and doxorubicin for 15 min.  We 
used the number of Hoechst stained objects in Ch1 to count the number of cells that were analyzed 
in the acquired images and demonstrated that the cell counts were consistent for 2D Cal33 cultures 
exposed to the indicated concentrations of the 4 compounds (up to 25µM), and that the fluorescent 
signals obtained were from the same cell numbers (Figure 17).  Figure 17B shows the integrated 
fluorescent intensities (RFUs) extracted from Ch2 (FITC, green) images of 2D Cal33 cultures after 
exposure to the indicated concentrations of ellipticine or idarubicin. The integrated RFUs for 
ellipticine and idarubicin increased linearly with respect to compound concentration. Figure 17 
shows the integrated (RFUs) extracted from Ch3 (TRITC, red) images of 2D Cal33 cultures after 
exposure to the indicated concentrations of idarubicin, daunorubicin and doxorubicin. The RFUs 
for idarubicin, daunorubicin and doxorubicin increased linearly with respect to compound 
concentration. The linear correlation of the RFUs with the concentrations of idarubicin, 
daunorubicin and doxorubicin (Figure 17), is consistent with the linear correlation observed 
between the RFU’s and compound concentrations in solution (Figure 8, Figure 9 & Figure 10). 
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Figure 17 Fluorescent intensity of 2D Cal33 cells seeded at 1000 cells/well and exposed to the indicated 
concentrations of the 4 compounds. Fluorescent intensity in 2D cell cultures from (A) Ch-1 Hoechst; (B) Ch-2 FITC; 
(C) Ch-3 TRITC. 
 
Normal tissue culture microplates were seeded at 1000 cells/well of Cal33 HNSCC cells. Cell monolayers 
were exposed to the indicated concentrations of ellipticine, idarubicin, daunorubicin and doxorubicin for 15 min. 2D 
Cal33 monolayers were fixed and stained in 3.7% Formaldehyde and Hoechst 33342. Fluorescent intensities of 4 
compounds were acquired on IXM and analyzed using the MWCS image analysis module. Each concentration well 
was in triplicates and the assay was repeated at least three times. R-square of linear regression for ellipticine and 
idarubicin in Ch 2 is 0.7489 and 0.9546, respectively. R-square of linear regression for idarubicin, daunorubicin and 
doxorubicin in Ch 3 is 0.9744, 0.9726 and 0.7998, respectively. The data represent the mean ± SD of triplicates 
determination from one of these independent experiments, 
 
 
 Then we conducted experiments to determine the concentration dependent penetration of 
ellipticine, idarubicin, daunorubicin and doxorubicin into 3D Cal33 tumor spheroids. Cal33 cells 
that had been seeded into 384-well ULA microplates were cultured overnight and then exposed to 
the indicated concentrations of the 4 compounds for 15-min. The 3D tumor spheroids were then 
fixed in 3.7% formaldehyde containing Hoechst-33342 for 45 min, and then washed by repeated 
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aspiration and rinsing with PBS on JANUS MDT automated lipid handling workstation. We then 
utilized the IXM automated imaging system to acquire images sequentially in Ch 1 Hoechst (blue), 
Ch 2 FITC (green) and Ch 3 TRITC (red) fluorescent channels. Hoechst 33342 DNA staining in 
Ch 1 was used to identify the nuclei of Cal33 cells and to define a mask of the in 3D tumor 
spheroids. Similar to the results in 2D cell cultures, fluorescent images in Ch2 (FITC) and Ch3 
(TRITC) of 2D Cal33 cell cultures exposed to idarubicin produced strong fluorescent signals in 
Ch2 and Ch3, and the color composite images showed a combination of blue (Hoechst staining), 
together with strong green and red signals that were predominantly yellow (Figure 18).  
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Figure 18 Grayscale and color composite images of 3D Cal33 HNSCC tumor spheroids + idarubicin treatment. (A) 
Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale images of idarubicin-treated (Ch 2 and Ch 3) 
and color composite images of Ch 1, Ch 2 and Ch 3 Cal33 HNSCC cells. 
 
384-well ULA microplates were seeded by 5000 cells per well of Cal33 HNSCC cells. 5μL of idarubicin were 
added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 The 2D microplate was fixed 
and stained in 3.7% formaldehyde containing Hoechst-33342. The ULA microplates were washed by PBS for three 
times after the 45-min fixation. Images were then acquired on the IXM High-Content Analysis System and analyzed 
using MWCS image analysis module. The images are presented are representative of similar images obtained in at 
least 3 independent experiments. 
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Figure 19 Grayscale and color composite images of 3D Cal33 HNSCC tumor spheroids + daunorubicin treatment. 
(A) Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale images of daunorubicin-treated (Ch 2 and 
Ch 3) and color composite images of Ch 1, Ch 2 and Ch 3 Cal33 HNSCC cells. 
 
384-well ULA microplates were seeded by 5000 cells per well of Cal33 HNSCC cells. 5μL of daunorubicin 
were added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 The 2D microplate was 
fixed and stained in 3.7% formaldehyde containing Hoechst-33342. The ULA microplates were washed by PBS for 
three times after the 45-min fixation. Images were then acquired on the IXM High-Content Analysis System and 
analyzed using MWCS image analysis module. The images are presented are representative of similar images 
obtained in at least 3 independent experiments. 
 
 
Daunorubicin and doxorubicin-exposed 3D tumor spheroids were also fluorescent in the 
images from the green (Ch 2) and red (Ch 3) channels but the red signal predominates making the 
 50 
color composite images of the spheroids purple due to the blue (Hoechst staining) and strong red 
signal (Figure 19 & Figure 20).   
Figure 20 Grayscale and color composite images of 3D Cal33 HNSCC tumor spheroids + doxorubicin treatment. 
(A) Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale images of doxorubicin-treated (Ch 2 and 
Ch 3) and color composite images of Ch 1, Ch 2 and Ch 3 Cal33 HNSCC cells. 
 
384-well ULA microplates were seeded by 5000 cells per well of Cal33 HNSCC cells. 5μL of doxorubicin 
were added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 The 2D microplate was 
fixed and stained in 3.7% formaldehyde containing Hoechst-33342. The ULA microplates were washed by PBS for 
three times after the 45-min fixation. Images were then acquired on the IXM High-Content Analysis System and 
analyzed using MWCS image analysis module. The images are presented are representative of similar images 
obtained in at least 3 independent experiments. 
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Also, the fluorescence images of 3D tumor spheroids exposed to ellipticine are shown in 
Figure 21. These images exhibited strong fluorescent signals in the green channel (Ch2, FITC), 
and the color composite images showed a combination of blue (Hoechst staining) together with a 
strong green signal (Figure 21).   
  
Figure 21 Grayscale and color composite images of 3D Cal33 HNSCC tumor spheroids + ellipticine treatment. (A) 
Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale images of ellipticine-treated (Ch 2) and color 
composite images of Ch 1 and Ch 2 Cal33 HNSCC cells. 
 
384-well ULA microplates were seeded by 5000 cells per well of Cal33 HNSCC cells. 5μL of ellipticine were 
added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 The 2D microplate was fixed 
and stained in 3.7% formaldehyde containing Hoechst-33342. The ULA microplates were washed by PBS for three 
times after the 45-min fixation. Images were then acquired on the IXM High-Content Analysis System and analyzed 
using MWCS image analysis module. The images are presented are representative of similar images obtained in at 
least 3 independent experiments. 
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Fluorescent intensity values were quantified from images of 3D Cal33 tumor spheroids 
exposed to the indicated concentrations of ellipticine, idarubicin, daunorubicin and doxorubicin. 
The algorithm uses the Hoechst DNA stain to create a spheroid mask in order to define the outline 
and area of the 3D spheroid. The algorithm then uses the spheroid mask and user set thresholds in 
the FITC (Ch2, green) and TRITC (Ch3, red) channels to create a spheroid mask in each channel 
and outputs the average and integrated fluorescent intensity signals from within the spheroid 
masks. Figure 22  portrays the integrated fluorescent intensity measurements obtained in the 
images of 3D tumor spheroids exposed to the indicated concentrations of ellipticine, idarubicin, 
daunorubicin, and doxorubicin for 15 min. These data show the integrated RFUs for ellipticine, 
idarubicin daunorubicin and doxorubicin increased linearly with respect to compound 
concentration (Figure 22). The linear correlation of the RFUs and the concentrations of idarubicin, 
daunorubicin and doxorubicin added to 3D tumor spheroids (Figure 22), is consistent with the 
linear relationship observed in 2D cell cultures (Figure 17) and compounds in solution (Figure 8, 
Figure 9 & Figure 10).  
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Figure 22 Fluorescent intensity of 3D Cal33 spheroids seeded 5000 cells/well and exposed to the indicated 
concentrations of the 4 compounds. Fluorescent intensity in 3D Cal33 spheroids from (A) Ch-1 Hoechst; (B) Ch-2 
FITC; (C) Ch-3 TRITC. 
 
384-well ULA microplates were seeded by 5000 Cal33 HNSCC cells per well as previously described. 5μL 
of ellipticine were added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 The 3D 
microplate was fixed by adding 50μL of 37% formaldehyde containing Hoechst-33342. The 3D microplates were 
washed by PBS for three times after the 45-min fixation. Images were then acquired on the ImageXpress Micro (IXM) 
High-Content Analysis System and analyzed. The images presented are representative of similar images obtained in 
at least 3 independent experiments. The quantitative data presented were extracted from the digital images using 
MWCS image analysis module. R-square of linear regression for ellipticine and idarubicin in Ch 2 is 0.9251 and 
0.9199, respectively. R-square of linear regression for idarubicin, daunorubicin and doxorubicin in Ch 3 is 0.8908, 
0.9710and 0.8570, respectively. The data represent the mean ± SD of triplicates determination from one of these 
independent experiments. 
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3.3.2 TIME DEPENTENT PENETRATION OF 2D AND 3D CULTURES 
To evaluate the time dependent penetration of ellipticine, idarubicin, daunorubicin and 
doxorubicin in 2D cell cultures assays, we exposed Cal33 HNSCC cells seeded in 2D cull cultures 
to 10μM of four compounds for the indicated time period.  The 2D cell cultures were then fixed in 
3.7% formaldehyde containing Hoechst-33342 for 45 min, and then washed by repeated aspiration 
and rinsing with PBS. We then utilized the IXM automated imaging system to acquire images 
sequentially in Ch 1 Hoechst (blue), Ch 2 FITC (green) and Ch 3 TRITC (red) fluorescent 
channels. Hoechst 33342 DNA staining in Ch 1 was used to identify the nuclei of Cal33 cells in 
2D cell cultures. The color composite overlays of the Ch 1, Ch 2 and Ch 3 fluorescent images of 
Hoechst stained nuclei are predominantly blue, which indicates that the Hoechst staining only 
fluoresces in Ch 1 (Figure 23). 
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Figure 23 Selected grayscale and color composite images of 2D Cal33 HNSCC cell culture + Hoechst staining for 
indicated exposure time. (A) Greyscale images of Hoechst 33342-stained nuclei (Ch 1) and color composite images 
of Ch 1, Ch 2 and Ch 3 Cal33 HNSCC cells. 
 
Normal tissue culture microplates were seeded by 1000 Cal33 HNSCC cells per well as previously described. 
The 2D microplates were fixed in 3.7% formaldehyde. The 2D microplates were washed by PBS for three times after 
the 45-min fixation. Images were then acquired on the ImageXpress Micro(IXM) High-Content Analysis System and 
analyzed using MWCS image analysis module. The images presented are representative of similar images obtained 
in at least 3 independent experiments.   
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Figure 24 Greyscale and color composite images of 2D Cal33 HNSCC cell culture + ellipticine treatment for 
indicated exposure time. (A) Greyscale images in Ch 1, greyscale images of ellipticine-treated in Ch 2 and color 
composite images of Ch 1, Ch 2 and Ch 3 Cal33 HNSCC cells. 
 
Normal tissue culture microplates were plated by Cal33 HNSCC cells as previously described. 5μL of 
ellipticine were added into wells at 0, 2.5 and 10 min time points. The 2D microplate was fixed and stained in 3.7% 
Formaldehyde and Hoechst. Images were acquired on the ImageXpress Micro(IXM) High-Content Analysis System 
and analyzed using MWCS image analysis module. Each concentration was in triplicates and the assay was repeated 
at least three times. 
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Fluorescent images in Ch2 of 2D Cal33 cell cultures exposed to ellipticine produced strong 
fluorescent signals, and the color composite images showed a combination of blue (Hoechst 
staining), together with strong green and red signals that was predominantly yellow (Figure 24).  
Figure 25 Grayscale and color composite images of 2D Cal33 HNSCC cell culture + idarubicin treatment for 
indicated exposure time. (A) Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale images of 
idarubicin-treated (Ch 2 and Ch 3) and color composite images of Ch 1 and Ch 2 Cal33 HNSCC cells. 
 
Normal tissue culture microplates were plated by Cal33 HNSCC cells as previously described. 5μL of 
idarubicin were added into wells at 0, 2.5 and 10 min time points. The 2D microplate was fixed and stained in 3.7% 
Formaldehyde and Hoechst. Images were acquired on the ImageXpress Micro(IXM) High-Content Analysis System 
and analyzed using MWCS image analysis module. Each concentration was in triplicates and the assay was repeated 
at least three times. 
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Fluorescent images in Ch2 (FITC) and Ch3 (TRITC) of 2D Cal33 cell cultures exposed to 
idarubicin produced strong fluorescent signals, and the color composite images showed a 
combination of blue (Hoechst staining), together with strong green and red signals that was 
predominantly yellow (Figure 25).  
Daunorubicin and doxorubicin-exposed cells were also fluorescent in the images from the green 
(Ch 2) and red (Ch 3) channels but the red signal predominates making the color composite image 
purple due to the blue (Hoechst staining) and strong red signal (Figure 26 & Figure 27). The 
Hoechst fluorescent signal (Ch1) appeared to be significantly less intense in 2D Cal33 cells that 
were exposed to daunorubicin and doxorubicin compared to cells that were not exposed to 
compounds (Compare Figure 26 & Figure 27 to Figure 23). 
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Figure 26 Selected grayscale and color composite images of 2D Cal33 HNSCC cell culture + daunorubicin 
treatment for indicated exposure time. (A) Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale 
images of daunorubicin-treated (Ch 2 and Ch 3) and color composite images of Ch 1 and Ch 2 Cal33 HNSCC cells. 
 
Normal tissue culture microplates were plated by Cal33 HNSCC cells as previously described. 5μL of 
daunorubicin were added into wells at 0, 2.5 and 10 min time points. The 2D microplates were fixed and stained in 
3.7% Formaldehyde and Hoechst 33342. Images were acquired on the ImageXpress Micro(IXM) High-Content 
Analysis System and analyzed using MWCS image analysis module. Each concentration was in triplicates and the 
assay was repeated at least three times. 
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Figure 27 Selected grayscale and color composite images of 2D Cal33 HNSCC cell culture + doxorubicin treatment 
for indicated exposure time. (A) Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale images of 
doxorubicin-treated (Ch 2 and Ch 3) and color composite images of Ch 1 and Ch 2 Cal33 HNSCC cells. 
 
Normal tissue culture microplates were plated by Cal33 HNSCC cells as previously described. 5μL of 
doxorubicin were added into wells at 0, 2.5 and 10 min time points. The 2D microplates were fixed and stained in 
3.7% Formaldehyde and Hoechst 33342. Images were acquired on the ImageXpress Micro(IXM) High-Content 
Analysis System and analyzed using MWCS image analysis module. Each concentration was in triplicates and the 
assay was repeated at least three times. 
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Figure 28 portrays the integrated fluorescent intensity measurements obtained in 2D Cal33 
cell cultures exposed to 10µM of the 4 drugs for up to 45 minutes.  We used the number of Hoechst 
stained objects in Ch 1 to count the number of cells that were analyzed in the acquired images and 
demonstrated that the cell counts were consistent for 2D Cal33 cultures exposed to 10µM of the 4 
compounds throughout the 45min time period (Figure 28).  Figure 28 shows the integrated 
fluorescent intensities (RFUs) extracted from Ch 1 (DAPI, blue) images of 2D Cal33 cultures 
stained with Hoechst-33342 at periods throughout the 45 min time period. The integrated RFUs 
for Hoechst increased in a roughly linear fashion through 10 min of Hoechst exposure to reach a 
maximum plateau that was maintained though 45 min in the continuous presence of the dye (Figure 
28). Figure 28 demonstrates that the RFUs extracted from Ch2 (FITC, green) images of 2D Cal33 
cultures exposed to 10µM of ellipticine and idarubicin for indicated time periods. The time course 
of ellipticine and idarubicin accumulation in the Ch 2 FITC images of 2D Cal33 cells followed a 
very similar pattern to Hoechst, with a rapid initial linear uptake phase that reached a maximum 
plateau between 5-10 min and was maintained through 45 min.  (Figure 28). Figure 26D shows 
the RFUs extracted from Ch3 (TRITC, red) images of 2D Cal33 cultures exposed to 10µM of 
idarubicin, daunorubicin and doxorubicin over 45 min. Again, the RFUs for idarubicin, 
daunorubicin and doxorubicin cellular accumulation increased linearly with respect to drug 
exposure time through 10 min and then reached a maximum plateau with continuous exposure 
(Figure 28).  
 
 
 62 
Figure 28 Quantifying 2D Cal33 microplate time course assay by MWCS image analysis.  (A) Total cell 
counts of Cal33 HNSCC cells treated with ellipticine, idarubicin, daunorubicin and doxorubicin; Mean stain 
integrated intensity of (B) ellipticine and idarubicin in FITC filter (ch-2) for indicated exposure time. (C) 
idarubicin, daunorubicin and doxorubicin in TRITC filter (ch-3) for indicated exposure time. 
 
Normal tissue culture microplates were seeded by 1000 Cal33 HNSCC cells per well as previously described. 
5μL of 4 compounds were added into wells for indicated exposure time. Then the 2D microplate was fixed and stained 
in 3.7% formaldehyde containing Hoechst-33342. The 2D microplates were washed by PBS for three times after the 
45-min fixation. Images were then acquired on IXM High-Content Analysis System and analyzed. The images 
presented are representative of similar images obtained in at least 3 independent experiments. The quantitative data 
presented were extracted from the digital images using MWCS image analysis module. R-square of linear regression 
for Hoechst stained is 0.7752.  R-square of linear regression for ellipticine and idarubicin in Ch 2 is 0.7434 and 
0.8047, respectively. R-square of linear regression for idarubicin, daunorubicin and doxorubicin in Ch 3 is 0.8454, 
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0.8102, and 0.9268, respectively. The data represent the mean ± SD of triplicates determination from one of these 
independent experiments. 
 
 
We then conducted similar time course experiments to measure the accumulation of 
ellipticine, idarubicin, daunorubicin and doxorubicin into 3D Cal33 tumor spheroids. Cal33 cells 
that had been seeded into 384-well ULA microplates were cultured overnight and then exposed to 
10µM of the 4 compounds for the indicated exposure times. The 3D tumor spheroids were then 
fixed in 3.7% formaldehyde containing Hoechst-33342, and washed by repeated aspiration and 
rinsing with PBS on JANUS MDT automated lipid handling workstation. We then utilized the 
IXM automated imaging system to acquire images sequentially in Ch 1 Hoechst (blue), Ch 2 FITC 
(green) and Ch 3 TRITC (red) fluorescent channels.  
Similar to the results in 2D cell cultures, fluorescent images in Ch2 (FITC) of 2D Cal33 
cell cultures exposed to ellipticine produced strong fluorescent signals in Ch2, and the color 
composite images showed a combination of blue (Hoechst staining) and green signals (Figure 29). 
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Figure 29  Selected grayscale and color composite images of 3D Cal33 HNSCC tumor spheroids + ellipticine 
treatment for indicated exposure time. (A) Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale 
images of ellipticine-treated (Ch 2 and Ch 3) and color composite images of Ch 1 and Ch 2 Cal33 HNSCC cells. 
 
384-well ULA microplates were seeded by 5000 Cal33 HNSCC cells per well as previously described. 5μL 
of ellipticine was added into wells for indicated exposure time. The ULA microplates were then and stained in 3.7% 
formaldehyde containing Hoechst-33342. Then the ULA microplates were washed by PBS for three times after the 
45-min fixation. Images were acquired on the IXM High-Content Analysis System and analyzed using MWCS image 
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analysis module. The images presented are representative of similar images obtained in at least 3 independent 
experiments.   
 
 
Figure 30 Selected grayscale and color composite images of 3D Cal33 HNSCC tumor spheroids + idarubicin 
treatment for indicated exposure time. (A) Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale 
images of idarubicin-treated (Ch 2 and Ch 3) and color composite images of Ch 1 and Ch 2 Cal33 HNSCC cells 
.  
384-well ULA microplates were seeded by 5000 Cal33 HNSCC cells per well as previously described. 5μL 
of idarubicin was added into wells for indicated exposure time. The ULA microplates were then and stained in 3.7% 
formaldehyde containing Hoechst-33342. Then the ULA microplates were washed by PBS for three times after the 
45-min fixation. Images were acquired on the IXM High-Content Analysis System and analyzed using MWCS image 
analysis module. The images presented are representative of similar images obtained in at least 3 independent 
experiments.   
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Fluorescent images in Ch2 (FITC) and Ch3 (TRITC) of 2D Cal33 cell cultures exposed to 
idarubicin produced strong fluorescent signals in Ch2 and Ch3, and the color composite images 
showed a combination of blue (Hoechst staining), together with strong green and red signals that 
were predominantly yellow (Figure 30). 
 
Figure 31 Selected grayscale and color composite images of 3D Cal33 HNSCC tumor spheroids + daunorubicin 
treatment for indicated exposure time. (A) Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale 
images of daunorubicin-treated (Ch 2 and Ch 3) and color composite images of Ch 1 and Ch 2 Cal33 HNSCC cells. 
 
384-well ULA microplates were seeded by 5000 Cal33 HNSCC cells per well as previously described. 5μL 
of daunorubicin was added into wells for indicated exposure time. The ULA microplates were then and stained in 
3.7% formaldehyde containing Hoechst-33342. Then the ULA microplates were washed by PBS for three times after 
the 45-min fixation. Images were acquired on the IXM High-Content Analysis System and analyzed using MWCS 
image analysis module. The images presented are representative of similar images obtained in at least 3 independent 
experiments.   
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Daunorubicin and doxorubicin-exposed 3D tumor spheroids were also fluorescent in the 
images from the green (Ch 2) and red (Ch 3) channels but the red signal predominates making the 
color composite images of the spheroids purple due to the blue (Hoechst staining) and strong red 
signals (Figure 31 & Figure 32).  
 
Figure 32 Selected grayscale and color composite images of 3D Cal33 HNSCC tumor spheroids + doxorubicin 
treatment for indicated exposure time. (A) Greyscale images of Hoechst 33342-stained nuclei (Ch 1), greyscale 
images of daunorubicin-treated (Ch 2 and Ch 3) and color composite images of Ch 1 and Ch 2 Cal33 HNSCC cells.  
 
A 3D 384-well ULA microplate was seeded by 5000 Cal33 HNSCC cells per well as previously described. 5μL of 
doxorubicin was added into wells for indicated exposure time. The 3D microplate was then fixed by adding 50μL of 
37% formaldehyde containing Hoechst-33342. Then the 3D microplate was washed by PBS for three times after the 
45-min fixation. Images were acquired on the ImageXpress Micro(IXM) High-Content Analysis System and analyzed 
using MWCS image analysis module. The images presented are representative of similar images obtained in at least 
3 independent experiments.   
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 The time dependent accumulation of test compounds in 3D Cal33 HNSCC tumor 
spheroids (Figure 33) was consistent with the time dependent drug penetration observed in 2D cell 
cultures (Figure 33). The time course of drug accumulation in the Ch 2 FITC and Ch3 TRITC 
images of 3D Cal33 spheroids followed a very similar pattern to Hoechst, with a rapid initial linear 
uptake phase that reached a maximum plateau between 5-10 min and was maintained through 45 
min. 
 
Figure 33 Quantifying 3D Cal33 tumor spheroid time course assay by MWCS image analysis.  (A) Total 
cell counts of Cal33 HNSCC cells treated with ellipticine, idarubicin, daunorubicin and doxorubicin; Mean stain 
integrated intensity of (B) ellipticine and idarubicin in FITC filter (ch-2) for indicated exposure time. (C) 
idarubicin, daunorubicin and doxorubicin in TRITC filter (ch-3) for indicated exposure time. 
 
ULA microplates were seeded by 5000 Cal33 HNSCC cells per well as previously described. 5μL of 4 
compounds were added into wells for indicated exposure time. Then the 3D microplate was fixed and stained in 3.7% 
formaldehyde containing Hoechst-33342. The 3D microplates were washed by PBS for three times after the 45-min 
fixation. Images were then acquired on the IXM High-Content Analysis System and analyzed. The images presented 
are representative of similar images obtained in at least 3 independent experiments. The quantitative data presented 
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were extracted from the digital images using MWCS image analysis module as described in materials and methods. 
R-square of linear regression for Hoechst stained is 0.7752.  R-square of linear regression for ellipticine and 
idarubicin in Ch 2 is 0.7434 and 0.8047, respectively. R-square of linear regression for idarubicin, daunorubicin and 
doxorubicin in Ch 3 0.8454, 0.8102 and 0.9268, respectively. The data represent the mean ± SD of triplicates 
determination from one of these independent experiments. 
 
 
 
 
 
3.3.3 Cal33 HNSCC 2D & 3D SEEDING DENSITY ASSAYS AND PSEUDOCOLOR 
IMAGES OF 2D&3D CULTURES 
We conducted experiments to see if the cell density of our 2D and 3D HNSCC cultures 
would affect the drug penetration of ellipticine, idarubicin, daunorubicin and doxorubicin. 
Different cell numbers of Cal33 cells that had been seeded into normal tissue culture assay plates 
and were cultured overnight to form 2D monolayers were and then exposed to 10µM of the 
compounds for 15-min. These microplates were then fixed in 3.7% formaldehyde containing 
Hoechst-33342 for 45 min, and washed by repeated aspiration and rinsing with PBS. We then 
utilized the IXM automated imaging system to acquire images sequentially in Ch 1 Hoechst (blue), 
Ch 2 FITC (green) and Ch 3 TRITC (red) fluorescent channels. Hoechst 33342 DNA staining in 
Ch 1 was used to identify the nuclei of Cal33 cells in 2D cell cultures. Fluorescent images of 2D 
Cal33 cell cultures exposed to idarubicin in Ch2 (FITC) and Ch3 (TRITC) produced strong 
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fluorescent signals, and the color composite images showed a combination of blue, green and red 
signals in all of the indicated seeding densities (Figure 34).  
 
Figure 34 Greyscale and color composite of 2D Cal33 cell cultures exposed to 10µM idarubicin at 5000, 10000 and 
20000 cells/well. (A) Images of idarubicin treatment on 2D Cal33 cell culture from ch-1 hoechst, ch-2 FITC and 
color composite. 
 
Normal tissue culture microplates seeded by 5000, 10000 and 20,000 Cal33 HNSCC cells per well. 5μL of 
idarubicin was added into wells and incubated for 15 min. The final concentration in wells was 10μM as described in 
materials and methods section. The cells were fixed and stained in 3.7% Formaldehyde and Hoechst 33342. Images 
were acquired on IXM and analyzed using the MWCS image analysis module. Each concentration well was in 
triplicates and the assay was repeated at least three times. 
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Images of daunorubicin and doxorubicin-exposed Cal33 HNSCC cells seeded in normal tissue 
culture assay plates were also fluorescent in both the green (Ch 2) and red (Ch 3) channels at the 
indicated seeding densities (Figure 35) and the sub-cellular localization appeared to be 
predominantly nuclear co-localized with the Hoechst stained.  
 
Figure 35 Greyscale and color composite of 2D Cal33 cell cultures exposed to 10µM daunorubicin at 5000, 10000 
and 20000 cells/well. (A) Images of daunorubicin treatment on 2D Cal33 cell culture from ch-1 hoechst, ch-2 FITC 
and color composite. 
 
Normal tissue culture microplates were seeded by 5000, 10000 and 20,000 Cal33 HNSCC cells per well. 5μL 
of daunorubicin was added into wells and incubated for 15 min. The final concentration in wells was 10μM as 
described in materials and methods section. The cells were fixed and stained in 3.7% Formaldehyde and Hoechst 
33342. Images were acquired on IXM and analyzed using the MWCS image analysis module. Each concentration well 
was in triplicates and the assay was repeated at least three times. 
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The greyscale and color composite fluorescence images of 2D Cal33 cell cultures seeded 
at 5,000, 10,000 and 20,000 Cal33 cells per well and exposed to 10 uM ellipticine are shown in 
Figure 36). These images exhibited strong fluorescent signals in the green channel (Ch2, FITC), 
and the color composite images showed a combination of blue (Hoechst staining) together with a 
strong green signal (Figure 36). Similar images were observed in 2D Cal33 cell cultures exposed 
to different concentrations of the 4 drugs and for different time periods confirming that drug 
penetration of these fluorescent compounds can be evaluated 2D monolayer cultures seeded at 
different cell densities in normal tissue culture plates (Figure 26, Figure 27 & Figure 28). 
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Figure 36 Greyscale and color composite of 2D Cal33 cell cultures exposed to 10µM ellipticine at 5000, 10000 and 
20000 cells/well. (A) Images of ellipticine treatment on 2D Cal33 cell culture from ch-1 hoechst, ch-2 FITC and 
color composite. 
 
Normal tissue culture microplates were seeded by 5000, 10000 and 20,000 Cal33 HNSCC cells per well. 5μL 
of ellipticine was added into wells and incubated for 15 min. The final concentration in wells was 10μM as described 
in materials and methods section. The cells were fixed and stained in 3.7% Formaldehyde and Hoechst 33342. Images 
were acquired on IXM and analyzed using the MWCS image analysis module. Each concentration well was in 
triplicates and the assay was repeated at least three times. 
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Quantitative data from the digital images were extracted and analyzed by same algorithm 
and analysis module used in 2D Cal33 HNSCC concentration response assays. Figure 37 portrays 
the integrated fluorescent intensity measurements obtained in 2D HNSCC cell cultures at the 
indicated cell seeding densities and exposed to 10µM of ellipticine, idarubicin, daunorubicin, and 
doxorubicin for 15 min.  Although the absolute fluorescent intensity values for each compound 
are different, the integrated fluorescent intensities (RFUs) extracted from images of Cal33 cells 
exposed to compounds in Ch1, Ch2 and Ch3 fluorescent channels remained constant at all seeding 
densities suggesting that drug penetration and/or accumulation was independent of cell number 
(Figure 37).  Consistent with our previous observations, exposure to idarubicin, daunorubicin or 
doxorubicin reduced the Hoechst RFU values suggesting that these compound may compete for 
the same DNA binding site as Hoechst. These data indicate that all four fluorescent compounds 
penetrated 2D Cal33 cell cultures uniformly at all seeding densities (Figure 37). Therefore, the 
drug penetration of 10 μM ellipticine, idarubicin, daunorubicin, and doxorubicin for 15min 
exposure is not dependent on the cell numbers in 2D cell cultures. 
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Figure 37 Fluorescent intensity of 2D Cal33 cells seeded at different densities and exposed to 10 uM of the 4 
compounds. Fluorescent intensity in 2D cell cultures from (A) Average cell count of Cal33 cells of 2 10X images; (B) 
Ch-1 Hoechst; (C) Ch-2 FITC; (D) Ch-3 TRITC. 
 
Normal tissue culture microplates were seeded at the indicated seeding densities of Cal33 HNSCC cells. Cell 
monolayers were exposed to ellipticine, idarubicin, daunorubicin and doxorubicin for 15 min. The final concentration 
in wells was 10μM. 2D Cal33 monolayers were fixed and stained in 3.7% Formaldehyde and Hoechst 33342. 
Fluorescent intensities of 4 compounds were acquired on IXM and analyzed using the MWCS image analysis module. 
Each concentration well was in triplicates and the assay was repeated at least three times. 
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We used the same methods to investigate the drug penetration of ellipticine, idarubicin, 
daunorubicin and doxorubicin into different sized Cal33 HNSCC spheroids formed in ULA plates 
seeded at different cell seeding densities. Different numbers of Cal33 cells that had been seeded 
into spheroids 384-well ULA microplates were cultured overnight and then exposed to 10µM of 
the compounds for 15-min. These microplates were then fixed in 3.7% formaldehyde containing 
Hoechst-33342 for 45 min, and washed by repeated aspiration and rinsing with PBS. We then 
utilized the IXM to acquire images sequentially in Ch 1 Hoechst (blue), Ch 2 FITC (green) and Ch 
3 TRITC (red) fluorescent channels. Hoechst 33342 DNA staining in Ch 1 was used to identify 
the nuclei of Cal33 cells in 3D cell cultures and create a spheroid mask to measure the integrated 
fluorescent intensities in Ch1, Ch2 and Ch3. Fluorescent images of 3D tumor spheroid exposed to 
idarubicin from Ch 2 and Ch 3 produced strong fluorescent signals, and the color composite images 
showed a combination of blue, green and red signals in differently sized spheroids formed from 
the indicated seeding densities (Figure 38).  
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Figure 38 Greyscale and color composite of 3D Cal33 spheroids exposed to 10µM idarubicin at 5000, 10000 and 
20000 cells/well. (A) Images of idarubicin treatment on 3D Cal33 spheroids from ch-1 hoechst, ch-2 FITC and 
color composite. 
 
 
384-well ULA microplates were seeded by 5000, 10000 and 20,000 Cal33 HNSCC cells per well. 5μL of 
idarubicin was added into wells and incubated for 15 min. The final concentration in wells was 10μM as described in 
materials and methods section. The cells were fixed and stained in 3.7% Formaldehyde and Hoechst 33342. Images 
were acquired on IXM and analyzed using the MWCS image analysis module. Each concentration well was in 
triplicates and the assay was repeated at least three times. 
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Figure 39 Greyscale and color composite of 3D Cal33 spheroids exposed to 10µM daunorubicin at 5000, 10000 
and 20000 cells/well. (A) Images of daunorubicin treatment on 3D Cal33 spheroids from ch-1 hoechst, ch-2 FITC 
and color composite. 
 
384-well ULA microplates were seeded by 5000, 10000 and 20,000 Cal33 HNSCC cells per well. 5μL of 
daunorubicin was added into wells and incubated for 15 min. The final concentration in wells was 10μM as described 
in materials and methods section. The cells were fixed and stained in 3.7% Formaldehyde and Hoechst 33342. Images 
were acquired on IXM and analyzed using the MWCS image analysis module. Each concentration well was in 
triplicates and the assay was repeated at least three times. 
 
Images of daunorubicin or doxorubicin-treated Cal33 HNSCC cells seeded in 384-well 
ULA microplates were also fluorescent in both the green (Ch 2) and red (Ch 3) channels in 
indicated seeding densities (Figure 39 & Figure 40).  
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Figure 40 Greyscale and color composite of 3D Cal33 spheroids exposed to 10µM doxorubicin at 5000, 10000 and 
20000 cells/well. (A) Images of doxorubicin treatment on 3D Cal33 spheroids from ch-1 hoechst, ch-2 FITC and 
color composite. 
 
384-well ULA microplates were seeded by 5000, 10000 and 20,000 Cal33 HNSCC cells per well. 5μL of 
doxorubicin was added into wells and incubated for 15 min. The final concentration in wells was 10μM as described 
in materials and methods section. The cells were fixed and stained in 3.7% Formaldehyde and Hoechst 33342. Images 
were acquired on IXM and analyzed using the MWCS image analysis module. Each concentration well was in 
triplicates and the assay was repeated at least three times. 
 
 
The fluorescence images of 3D cell cultures differently sized Cal33 spheroids formed in 
ULA plates seeded at 5,000, 10,000 and 20,000 Cal33 cells per well treated by ellipticine are 
shown in Figure 41. The images of Cal33 spheroids exposed to ellipticine exhibited strong 
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fluorescent signals in the green channel (Ch2, FITC), and the color composite images showed a 
combination of blue (Hoechst staining) together with a strong green signal (Figure 41). 
Figure 41 Greyscale and color composite of 3D Cal33 spheroids exposed to 10µM ellipticine at 5000, 10000 and 
20000 cells/well. (A) Images of ellipticine treatment on 3D Cal33 spheroids from ch-1 hoechst, ch-2 FITC and 
color composite. 
 
384-well ULA microplates were seeded by 5000, 10000 and 20,000 Cal33 HNSCC cells per well. 5μL of 
ellipticine was added into wells and incubated for 15 min. The final concentration in wells was 10μM as described in 
materials and methods section. The cells were fixed and stained in 3.7% Formaldehyde and Hoechst 33342. Images 
were acquired on IXM and analyzed using the MWCS image analysis module. Each concentration well was in 
triplicates and the assay was repeated at least three times. 
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In marked contrast to 2D Cal33 cell monolayers, the fluorescent signals were detected in 
3D Cal33 spheroids when cells exposed to the four compounds exhibited a strong dependence of 
cell numbers and corresponding size of the spheroids produced. (Figure 42). The fluorescent 
intensities extracted from images of Cal33 3D tumor spheroids increased as the seeding densities 
(Figure 42). The data suggests that more compounds accumulated into the 3D Cal33 spheroids as 
the size of the 3D tumor spheroids formed increased. The images demonstrate that the size of the 
Cal33 tumor spheroids formed (width, area and volume) is dependent upon the number of cells 
added to the wells of the ULA plates and that the larger the spheroid the more drug accumulates 
(Figure 38, Figure 39, Figure 40 & Figure 41). Furthermore, the overall fluorescent intensities 
extracted from images of 3D tumor spheroids are >10-fold higher than for 2D cell cultures. Images 
of Cal33 HNSCC cells seeded into 2D assay plates indicate that even at higher densities the cal33 
cells do not appear to form many cell-cell contacts (Figure 34, Figure 35, Figure 36, Figure 38, 
Figure 39, Figure 40 & Figure 41). Whereas, Cal33 tumor spheroids form a compact three-
dimensional architecture of cells that are in direct contact with other cells (Figure 38, Figure 39, 
Figure 40 & Figure 41). These images and data demonstrate that the penetration of compounds 
may be hampered by the physical and physiological barrier of 3D tumor spheroids, which prevents 
drugs from getting into the spheroids. In contrast, the drugs can easily penetrate into the tumor 
cells in 2D cell cultures where cells grow without cell-cell contacts and three-dimensional 
architectures. (Figure 34, Figure 35 & Figure 36). 
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Figure 42  Fluorescent intensity of 3D Cal33 spheroids seeded at different densities and exposed to 10 uM of the 
4 compounds. Fluorescent intensity in 3D Cal33 spheroids from (A) Ch-1 Hoechst; (B) Ch-2 FITC; (C) Ch-3 TRITC. 
 
 384-well ULA microplates were seeded at the indicated seeding densities of Cal33 HNSCC cells. 3D Cal33 
spheroids were exposed to ellipticine, idarubicin, daunorubicin and doxorubicin for 15 min. The final concentration 
in wells was 10μM. 3D Cal33 spheroids were fixed and stained in 3.7% Formaldehyde and Hoechst 33342. 
Fluorescent intensities of 4 compounds were acquired on IXM and analyzed using the MWCS image analysis module. 
Each concentration well was in triplicates and the assay was repeated at least three times. 
 
 
To evaluate drug penetration in 2D and 3D cultures, representative images are presented in pseudo-
color format where the relative fluorescent intensities inside the 2D cell or 3D tumor spheroid are 
indicated by the different colors. “Hotter” and “brighter” colors (white, red, yellow) represent the 
higher intensity signals of compounds and blue or purple represent lower intensity signals. The 
same color range was set to apply for images of cells at different seeding densities. For all four 
drugs, the corresponding pseudo-color images at all seeding densities tested indicate that there is 
no significant drug penetration gradient in 2D cell cultures, and the fluorescent intensity 
measurements were constant at all densities, suggesting that drug penetration and/or accumulation 
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was independent of cell number. In marked contrast, rainbow-like color rings were observed in the 
pseudo-color images of Cal33 HNSCC cells in 3D tumor spheroids exposed to the 4 drugs. “Hotter” 
colors are present at the outer layers of the 3D tumor spheroids, and the temperature of the colors 
decrease towards the core of the spheroids. These images indicate that a significant drug 
penetration gradient with all four drugs in Cal33 HNSCC 3D tumor spheroids (Figure 43). 
 
 Figure 43 Pseudo-color images of Cal33 HNSCC cells in 2D cultures and 3D tumor spheroids exposed to 10µM 
ellipticine at 5,000, 10,000 and 20,000 cells/well. (A) Pseudocolor images from ch-2 FITC in 2D cell cultures; (B) 
Pseudocolor images from ch-2 FITC in 3D tumor spheroids. 
 
 Normal tissue culture microplates and 384-well ULA microplates were seeded by 5000, 10000 and 20,000 
Cal33 HNSCC cells per well. 5μL of ellipticine was added into wells and incubated for 15 min. The final concentration 
of ellipticine in wells was 10μM 
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Figure 44 Pseudo-color images of Cal33 HNSCC cells in 2D cultures and 3D tumor spheroids exposed to 10µM 
idarubicin at 5,000, 10,000 and 20,000 cells/well. (A) Pseudocolor images from ch-2 FITC in 2D cell cultures; (B) 
Pseudocolor images from ch-2 FITC in 3D tumor spheroids. 
 
Normal tissue culture microplates and 384-well ULA microplates were seeded by 5000, 10000 and 20,000 
Cal33 HNSCC cells per well. 5μL of idarubicin was added into wells and incubated for 15 min. The final concentration 
of ellipticine in wells was 10μM. 
 
Similar phenomenon was also observed in images of Cal33 cells treated with idarubicin in 
2D cell cultures and 3D tumor spheroids from Ch 3 (Figure 44). Fluorescent intensity within Cal33 
2D cell cultures was consistent throughout the images, whereas, a clear gradient of fluorescent 
intensity was detected inside the 3D tumor spheroids. These images indicate that a significant drug 
penetration gradient of idarubicin was shown in Cal33 HNSCC 3D tumor spheroids other than 2D 
cell cultures (Figure 44). 
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As we observed from images of Cal33 cells treated with ellipticine or idarubicin, both 
daunorubicin and doxorubicin showed a uniform distribution in 2D cell cultures and a significant 
drug penetration gradient in 3D tumor spheroids as well (Figure 45 & Figure 46). 
Figure 45 Pseudo-color images of Cal33 HNSCC cells in 2D cultures and 3D tumor spheroids exposed to 10µM 
daunorubicin at 5,000, 10,000 and 20,000 cells/well. (A) Pseudocolor images from ch-2 FITC in 2D cell cultures; 
(B) Pseudocolor images from ch-2 FITC in 3D tumor spheroids. 
 
Normal tissue culture microplates and 384-well ULA microplates were seeded by 5000, 10000 and 20,000 
Cal33 HNSCC cells per well. 5μL of daunorubicin was added into wells and incubated for 15 min. The final 
concentration of ellipticine in wells was 10μM 
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Figure 46 Pseudo-color images of Cal33 HNSCC cells in 2D cultures and 3D tumor spheroids exposed to 10µM 
doxorubicin at 5,000, 10,000 and 20,000 cells/well. (A) Pseudocolor images from ch-2 FITC in 2D cell cultures; 
(B) Pseudocolor images from ch-2 FITC in 3D tumor spheroids. 
 
Normal tissue culture microplates and 384-well ULA microplates were seeded by 5000, 10000 and 20,000 
Cal33 HNSCC cells per well. 5μL of doxorubicin was added into wells and incubated for 15 min. The final 
concentration of ellipticine in wells was 10μM. 
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3.3.4 FADU HNSCC 3D CONCENTRATION DEPENDENT ASSAY 
Furthermore, we conducted experiments to determine the concentration dependent 
penetration of ellipticine, idarubicin, daunorubicin and doxorubicin on FADU HNSCC cell line in 
384-well ULA microplate. Also, the fluorescence images of 3D FADU tumor spheroids exposed 
to ellipticine are shown in Figure 47. These images exhibited strong fluorescent signals in the 
green channel (Ch2, FITC), and the color composite images showed a combination of blue 
(Hoechst staining) together with a strong green signal (Figure 47). furthermore, the pseudo-color 
images of 3D FADU spheroids exposed to 12.5µM ellipticine indicate a clear gradient of 
fluorescent intensity was detected inside the 3D tumor spheroids at 5,000, 10,000 and 20,000 
cells/well (Figure 47). These images indicate that a significant drug penetration gradient of 
ellipticine was shown in 3D FADU HNSCC tumor spheroids, same as Cal33 cells in 3D tumor 
spheroids (Figure 43, Figure 44, Figure 45 & Figure 46). 
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Figure 47 Grayscale and color composite images of 3D FADU HNSCC tumor spheroids + ellipticine treatment. 
(A) Greyscale and color composite images of ellipticine-treated (Ch 2) and pseudo-color images of 3D FADU 
HNSCC spheroids; (B) Color range of pseudo-color images. 
 
384-well ULA microplates were seeded by 5000 cells per well of FADU HNSCC cells. 5μL of ellipticine were 
added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 The 2D microplate was fixed 
and stained in 3.7% formaldehyde containing Hoechst-33342. The ULA microplates were washed by PBS for three 
times after the 45-min fixation. Images were then acquired on the IXM High-Content Analysis System and analyzed 
using MWCS image analysis module. The images are presented are representative of similar images obtained in at 
least 3 independent experiments. 
 
As we observed from images of Cal33 cells exposed to idarubicin in 3D tumor spheroids (Fig. 44), 
fluorescent images of 3D tumor spheroid exposed to idarubicin from Ch 2 and Ch 3 produced 
strong fluorescent signals, and the color composite images showed a combination of blue, green 
and red signals in differently sized spheroids formed from the indicated seeding densities (Figure 
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48). the pseudo-color images of FADU cells in 3D tumor spheroids also indicate a gradient a clear 
gradient of fluorescent intensity at 5,000, 10,000 and 20,000 cells/well (Figure 48), which has been 
shown in the images of Cal33 cells exposed to idarubicin and seeded in 384-well ULA microplates 
(Figure 44). 
Figure 48  Grayscale and color composite images of 3D FADU HNSCC tumor spheroids + idarubicin treatment. 
(A) Greyscale and color composite images of ellipticine-treated (Ch 3) and pseudo-color images of 3D FADU 
HNSCC spheroids; (B) Color range of pseudo-color images. 
 
384-well ULA microplates were seeded by 5000 cells per well of FADU HNSCC cells. 5μL of idarubicin 
were added into wells with indicated concentration. After 15 min incubation at 37℃, 5% CO2 The 2D microplate was 
fixed and stained in 3.7% formaldehyde containing Hoechst-33342. The ULA microplates were washed by PBS for 
three times after the 45-min fixation. Images were then acquired on the IXM High-Content Analysis System and 
analyzed using MWCS image analysis module. The images are presented are representative of similar images 
obtained in at least 3 independent experiments. 
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  Fluorescent intensity values were quantified from images of 3D FADU tumor spheroids 
exposed to the indicated concentrations of ellipticine, idarubicin, daunorubicin and doxorubicin. 
Same 3D concentration dependent penetration assay protocol and quantification analysis method 
was conducted on FADU HNSCC cells. Figure 49 portrays the integrated fluorescent intensity 
measurements obtained in the images of 3D tumor spheroids exposed to the indicated 
concentrations of ellipticine, idarubicin, daunorubicin, and doxorubicin for 15 min. These data 
show the integrated RFUs for ellipticine, idarubicin daunorubicin and doxorubicin increased 
linearly with respect to compound concentration (Figure 49). The linear correlation of the RFUs 
and the concentrations of idarubicin, daunorubicin and doxorubicin added to 3D tumor spheroids 
(Figure 49), is consistent with the linear relationship observed in 3D Cal33 tumor spheroids (Figure 
20) and compounds in solution (Figure 8, Figure 9, Figure 10 & Figure 11). These data suggest 
that the 3D tumor spheroids formed in 384-well ULA microplates do not only amenable for Cal33 
HNSCC cells, but also other HNSCC cell lines, like FaDu. 
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Figure 49 Fluorescent intensity of 3D FADU spheroids seeded at different densities and exposed to 10 uM of the 4 
compounds. Fluorescent intensity in 3D FADU spheroids from (A) Ch-1 Hoechst; (B) Ch-2 FITC; (C) Ch-3 TRITC. 
 
384-well ULA microplates were seeded at the indicated seeding densities of FADU HNSCC cells. 3D FADU 
spheroids were exposed to the indicated concentration of ellipticine, idarubicin, daunorubicin and doxorubicin for 15 
min. 3D FADU spheroids were fixed and stained in 3.7% Formaldehyde and Hoechst 33342. Fluorescent intensities 
of 4 compounds were acquired on IXM and analyzed using the MWCS image analysis module. Each concentration 
well was in triplicates and the assay was repeated at least three times. 
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4.0  CONCLUSIONS 
We have successfully generated Cal33 and FaDu HNSCC tumor spheroids in 384-well 
ULA microplates to investigate and compare cytotoxicity and drug penetration in 2D and 3D Cal33 
cell cultures. Cal33 tumor spheroids were significantly (>5-fold) more resistant to growth 
inhibition by ellipticine, idarubicin, daunorubicin and doxorubicin than the corresponding 2D cell 
cultures. We first measured the absorbance and fluorescence spectra of the four compounds in 
solution and demonstrated a linear relationship between fluorescent intensity (RFUs) and the 
concentration of idarubicin, daunorubicin and doxorubicin. To measure and quantify drug 
penetration, accumulation and distribution in 2D and 3D cell cultures we used the IXM high 
content platform to acquire digital images of cells and spheroids in Ch 1 (Hoechst), Ch 2 (FITC) 
and Ch 3 (TRITC), and used the MWCS image analysis module to extract and quantify the 
fluorescence intensities of the four compounds. Although we could not detect ellipticine 
fluorescence in PBS, cells exposed to ellipticine exhibited a strong fluorescence in images captured 
in the FITC channel that could be quantified using the MWCS image analysis module. We 
speculate that ellipticine becomes fluorescent after it intercalates with DNA or after ellipticine-DNA 
adducts have been formed. Consistent with our observations in solution, in 2D and 3D Cal33 cell 
cultures exposed to idarubicin, daunorubicin, doxorubicin, or ellipticine, the mean integrated 
fluorescent intensity (RFU’s) detected in monolayer cells and spheroids increased linearly with 
respect to drug concentration. We conclude that the RFU’s of idarubicin, daunorubicin, 
doxorubicin and ellipticine can be used to infer the relative concentration of these drugs within the 
cells of monolayers and tumor spheroids. In concentration and time dependent drug penetration 
experiments, the accumulation of ellipticine, idarubicin, daunorubicin and doxorubicin into 2D 
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and 3D Cal33 cultures exhibited very similar concentration and time dependent behaviors. In 2D 
Cal33 cell seeding density experiments, elliptince, idarubicin, daunorubicin and doxorubicin 
accumulated uniformly in Cal33 cells independently of cell numbers. Even at the higher 2D cell 
seeding densities, the Cal33 cells do not appear to form many cell-cell contacts.  In marked 
contrast, the RFU’s detected in Cal33 spheroids exposed to the four drugs were higher as the 
number cells and corresponding spheroid sizes increased. The apparent differences in drug 
penetration and distribution within monolayer cells and spheroids were highlighted in the 
corresponding intensity gradient pseudo-color images. Cells in 3D spheroids exhibited a distinct 
fluorescent intensity gradient transitioning from high in the cells in the outside layers of the 
spheroid to low in cells in the inner core. The compacted three-dimensional multilayer architecture 
of spheroids promotes direct cell-cell contacts and cell-cell interactions that limit the diffusion and 
penetration of drugs throughout the spheroid. In order to reach the cells in the inner core of 
spheroids, drugs have to be taken up, pass through and then exit successive layers of cells. The 
larger the spheroid the more layers of cells the drugs need to penetrate and the longer this process 
is likely to take. In addition to representing a physical barrier to drug penetration and diffusion, it 
is possible that cell-cell contacts and cell-cell interactions might activate mechanisms that inhibit 
drug uptake and passage, or promote drug efflux. Our studies demonstrate that the cells in the 
interior of 3D tumor spheroids that are further from the spheroid surface experience lower drug 
concentrations than the cells in the exterior layers. In contrast the cells in 2D monolayer cultures 
are all exposed to same uniformed drug concentration. It has been observed that cells in the 
different regions or zones of spheroid cultures have different proliferative capacities; cells in the 
outer layers are actively proliferating, cells in the interior layer are quiescent, and in larger 
spheroids cells in the interior core may be necrotic. We speculate that the reduced penetration of 
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drugs into the interior cells of 3D tumor spheroids combined with the diminished proliferative 
capacity of these cells might contribute to the apparent resistance of 3D HNSCC spheroids to 
growth inhibition relative to 2D cultures exposed to these compounds. Based on the similarities 
between the microenvironments of cells in 3D tumor spheroid cultures and cell in solid tumors, 
and that cells in inner regions of spheroids are exposed to lower drug concentrations and have 
reduced proliferative capacities, we believe that incorporating 3D tumor models into the in vitro 
screening of cancer drugs will improve the correlation with in vivo efficacy in preclinical animal 
models and human clinical trials.  
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APPENDIX A 
ABBREVIATION 
1. National Cancer Institute ---NCI 
2. Central nervous system ---CNS 
3. Head and neck squamous cell carcinoma ---HNSCC 
4. Multidrug resistance ---MDR 
5. ATP-binding cassette transporter family ---ABC transporter family 
6. Breast cancer resistance protein ---BCRP 
7. Inhibitor of apoptosis proteins ---IAPs 
8. Mitochondrial membrane permeabilization ---MMP 
9. Extracellular matrix ---ECM 
10. Two-dimensional ---2D 
11. Three-dimensional ---3D 
12. U.S. Food and Drug Administration ---FDA 
13. Poly glycolic acid ---PGA 
14. Poly lactic acid ---PLA 
15. Ultra-low attachment ---ULA 
16. CellTiter-Glo ---CTG 
17. ImageXpress Micro ---IXM 
18. Human papillomavirus ---HPV 
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19. Green fluorescent protein ---GFP 
20. Red fluorescent protein ---RFP 
21. Cytochrome P450 ---CYP 
22. Phosphate-buffered saline ---PBS 
23. Dimethyl sulfoxide ---DMSO 
24. Fetal bovine serum ---FBS 
25. Penicillin/streptomycin ---P/S 
26. Dulbecco’s Modified Eagle’s Medium ---DMEM 
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